% alzhub.org library filter
% Source: https://alzhub.org/research?q=lecanemab
% 283 entries, in the order the page lists them. Built from alzhub.org's own records.
% 12 entries have no readable author in the source record and carry no author field.

@article{perry2026-41689888,
  author  = {Perry, Richard and Kipps, Christopher and Martín, Maria Eugenia Soto and Bozzali, Marco and Logroscino, Giancarlo and Trafford, Sarah and Dhadda, Shobha and Kanekiyo, Michio and others},
  title   = {{Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100507},
  pmid    = {41689888},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100507}
}

@article{terao2024-38253184,
  author  = {Terao, Itsuki and Kodama, Wakako},
  title   = {{Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2024},
  doi     = {10.1016/j.arr.2024.102203},
  pmid    = {38253184},
  url     = {https://doi.org/10.1016/j.arr.2024.102203}
}

@article{terao2025-40386876,
  author  = {Terao, Itsuki and Kodama, Wakako},
  title   = {{Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis}},
  journal = {Journal of psychopharmacology (Oxford, England)},
  year    = {2025},
  doi     = {10.1177/02698811251340901},
  pmid    = {40386876},
  url     = {https://doi.org/10.1177/02698811251340901}
}

@article{swanson2021-33865446,
  author  = {Swanson, C. J. and Zhang, Y. and Dhadda, S. and Wang, J. and Kaplow, J. and Lai, R. Y. K. and Lannfelt, L. and Bradley, H. and others},
  title   = {{A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00813-8},
  pmid    = {33865446},
  url     = {https://doi.org/10.1186/s13195-021-00813-8}
}

@article{mcdade2022-36544184,
  author  = {McDade, E. and Cummings, J. L. and Dhadda, S. and Swanson, C. J. and Reyderman, L. and Kanekiyo, M. and Koyama, A. and Irizarry, M. and others},
  title   = {{Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study}},
  journal = {Alzheimer's research \& therapy},
  year    = {2022},
  doi     = {10.1186/s13195-022-01124-2},
  pmid    = {36544184},
  url     = {https://doi.org/10.1186/s13195-022-01124-2}
}

@article{vandyck2023-36449413,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and others},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2212948},
  pmid    = {36449413},
  url     = {https://doi.org/10.1056/nejmoa2212948}
}

@article{chowdhury2023-37902139,
  author  = {Chowdhury, Selia and Chowdhury, Nurjahan Shipa},
  title   = {{Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review}},
  journal = {International journal of immunopathology and pharmacology},
  year    = {2023},
  doi     = {10.1177/03946320231209839},
  pmid    = {37902139},
  url     = {https://doi.org/10.1177/03946320231209839}
}

@article{solopova2023-38086820,
  author  = {Solopova, E. and Romero-Fernandez, W. and Harmsen, H. and Ventura-Antunes, L. and Wang, E. and Shostak, A. and Maldonado, J. and Donahue, M. J. and others},
  title   = {{Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease}},
  journal = {Nature communications},
  year    = {2023},
  doi     = {10.1038/s41467-023-43933-5},
  pmid    = {38086820},
  url     = {https://doi.org/10.1038/s41467-023-43933-5}
}

@article{honig2024-38730496,
  author  = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others},
  title   = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01441-8},
  pmid    = {38730496},
  url     = {https://doi.org/10.1186/s13195-024-01441-8}
}

@article{qiao2023-37213538,
  author  = {Qiao, Y. and Chi, Y. and Zhang, Q. and Ma, Y.},
  title   = {{Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials}},
  journal = {Frontiers in aging neuroscience},
  year    = {2023},
  doi     = {10.3389/fnagi.2023.1169499},
  pmid    = {37213538},
  url     = {https://doi.org/10.3389/fnagi.2023.1169499}
}

@article{hossain2024-38867460,
  author  = {Hossain, M. F. and Husna, A. U. and Kharel, M.},
  title   = {{Use of lecanemab for the treatment of Alzheimer's disease: A systematic review}},
  journal = {Brain and behavior},
  year    = {2024},
  doi     = {10.1002/brb3.3592},
  pmid    = {38867460},
  url     = {https://doi.org/10.1002/brb3.3592}
}

@article{cohen2023-37874099,
  author  = {Cohen, S and van Dyck, C H and Gee, M and Doherty, T and Kanekiyo, M and Dhadda, S and Li, D and Hersch, S and others},
  title   = {{Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.123},
  pmid    = {37874099},
  url     = {https://doi.org/10.14283/jpad.2023.123}
}

@article{vandyck2023-22dd8fce,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and Reyderman, L. and Cohen, S. and Froelich, L. and Katayama, S. and Sabbagh, M. and Vellas, B. and Watson, D. and Dhadda, S. and Irizarry, M. and Kramer, L. D. and Iwatsubo, T.},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {New England Journal of Medicine},
  year    = {2023},
  pmid    = {36449413}
}

@article{chen2025-41070709,
  author  = {Chen, S. and Ou, R. and Wei, Q. and Li, C. and Song, W. and Zhao, B. and Yang, J. and Fu, J. and others},
  title   = {{Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70750},
  pmid    = {41070709},
  url     = {https://doi.org/10.1002/alz.70750}
}

@article{kang2026-42535277,
  author  = {Kang, Sung Hoon and Park, Yu Jeong and Lee, Seungyun and Kang, Jimin and Lee, Seongin and Lee, Eun Seong and Jung, Hye Na and Ryoo, Inseon and others},
  title   = {{Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2026},
  doi     = {10.1002/alz.71705},
  pmid    = {42535277},
  url     = {https://doi.org/10.1002/alz.71705}
}

@article{wang2025-40308765,
  author  = {Wang, H. and Pan, J. and Zhang, M. and Tan, Z.},
  title   = {{Re-evaluation of the efficacy and safety of anti-Aβ monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1599048},
  pmid    = {40308765},
  url     = {https://doi.org/10.3389/fphar.2025.1599048}
}

@article{abdelazim2024-38565747,
  author  = {Abdelazim, K. and Allam, A. A. and Afifi, B. and Abdulazeem, H. and Elbehiry, A. I.},
  title   = {{The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}},
  journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
  year    = {2024},
  doi     = {10.1007/s10072-024-07477-w},
  pmid    = {38565747},
  url     = {https://doi.org/10.1007/s10072-024-07477-w}
}

@article{noguchishinohara2025-41276859,
  author  = {Noguchi-Shinohara, M. and Yoshinobu, T. and Ozaki, T. and Muramatsu, D. and Shima, A. and Sakashita, Y. and Tada, Y. and Yamaguchi, H. and others},
  title   = {{Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01912-6},
  pmid    = {41276859},
  url     = {https://doi.org/10.1186/s13195-025-01912-6}
}

@article{paczynski2025-40354064,
  author  = {Paczynski, M. and Hofmann, A. and Posey, Z. and Gregersen, M. and Rudman, M. and Ellington, D. and Aldinger, M. and Musiek, E. S. and Holtzman, D. M. and Bateman, R. J. and others},
  title   = {{Lecanemab Treatment in a Specialty Memory Clinic}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.1232},
  pmid    = {40354064},
  url     = {https://doi.org/10.1001/jamaneurol.2025.1232}
}

@article{knopman2023-37295957,
  author  = {Knopman, D. S. and Hershey, L.},
  title   = {{Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207438},
  pmid    = {37295957},
  url     = {https://doi.org/10.1212/wnl.0000000000207438}
}

@article{bregman2025-40437535,
  author  = {Bregman, N. and Nathan, T. and Shir, D. and Omer, N. and Levy, M. H. and David, A. B. and Aizenstien, O. and Lotan, E. and others},
  title   = {{Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01763-1},
  pmid    = {40437535},
  url     = {https://doi.org/10.1186/s13195-025-01763-1}
}

@article{shang2025-41250246,
  author  = {Shang, Jia and Zhong, Siyan and Shang, Li and Zeng, Qingze and Zhao, Shuai and Luo, Xiao and Li, Kaicheng and Zhang, Xinyi and others},
  title   = {{Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01886-5},
  pmid    = {41250246},
  url     = {https://doi.org/10.1186/s13195-025-01886-5}
}

@article{shimasaki2026-41936348,
  author  = {Shimasaki, Ryosuke and Kurihara, Masanori and Bannai, Taro and Hatano, Keiko and Suzuki, Fumio and Tokumaru, Aya Midori and Ishii, Kenji and Ihara, Ryoko and others},
  title   = {{Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100562},
  pmid    = {41936348},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100562}
}

@article{arroyopacheco2025-39638097,
  author  = {Arroyo-Pacheco, N. and Sarmiento-Blanco, S. and Vergara-Cadavid, G. and Castro-Leones, M. and Contreras-Puentes, N.},
  title   = {{Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2025},
  doi     = {10.1016/j.arr.2024.102620},
  pmid    = {39638097},
  url     = {https://doi.org/10.1016/j.arr.2024.102620}
}

@article{berry2023-37040116,
  author  = {Berry, D. A. and Dhadda, S. and Kanekiyo, M. and Li, D. and Swanson, C. J. and Irizarry, M. and Kramer, L. D. and Berry, S. M.},
  title   = {{Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2023},
  doi     = {10.1001/jamanetworkopen.2023.7230},
  pmid    = {37040116},
  url     = {https://doi.org/10.1001/jamanetworkopen.2023.7230}
}

@article{ashmawy2025-40232258,
  author  = {Ashmawy, R. E. and Okesanya, O. J. and Ukoaka, B. M. and Daniel, F. M. and Ezedigwe, S. G. and Agboola, A. O. and Ahmed, M. M. and Ogaya, J. B. and others},
  title   = {{Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidence}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2025},
  doi     = {10.1177/13872877251331640},
  pmid    = {40232258},
  url     = {https://doi.org/10.1177/13872877251331640}
}

@article{agosta2026-41857623,
  author  = {Agosta, Federica and Cecchetti, Giordano and Spinelli, Edoardo G and Ghirelli, Alma and Rugarli, Giulia and Pisano, Stefano and Coraglia, Federico and Canu, Elisa and others},
  title   = {{Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience}},
  journal = {Alzheimer's research \& therapy},
  year    = {2026},
  doi     = {10.1186/s13195-026-02015-6},
  pmid    = {41857623},
  url     = {https://doi.org/10.1186/s13195-026-02015-6}
}

@article{kang2026-42642841,
  author  = {Kang, Heekyoung and Jang, Hyemin and Ahn, Jehyun and Na, Duk L and Lee, Jae-Hong and Kim, Eun-Joo and Chun, Min Young and Cho, Soo Hyun and others},
  title   = {{APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2026},
  doi     = {10.1002/alz.71765},
  pmid    = {42642841},
  url     = {https://doi.org/10.1002/alz.71765}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{grill2024-37830926,
  author  = {Grill, J. D. and Flournoy, C. and Dhadda, S. and Ernstrom, K. and Sperling, R. and Molina-Henry, D. and Tranotti, K. and Harris, R. and others},
  title   = {{Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease}},
  journal = {Annals of neurology},
  year    = {2024},
  doi     = {10.1002/ana.26819},
  pmid    = {37830926},
  url     = {https://doi.org/10.1002/ana.26819}
}

@article{hakim2026-42661728,
  author  = {Hakim, Ryan and Harris, Kristofer and Merrill, Livia and Falk-Vargas, Amanda and Whalen, Eileen and Xia, Tianxu and Ochoa, Olga and Hunter, David and others},
  title   = {{Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab}},
  journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
  year    = {2026},
  doi     = {10.1002/dad2.70404},
  pmid    = {42661728},
  url     = {https://doi.org/10.1002/dad2.70404}
}

@article{nguyen2024-38484190,
  author  = {Nguyen, H. V. and Mital, S. and Knopman, D. S. and Alexander, G. C.},
  title   = {{Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/WNL.0000000000209218},
  pmid    = {38484190},
  url     = {https://doi.org/10.1212/WNL.0000000000209218}
}

@article{jeon2025-41225766,
  author  = {Jeon, So Yeon and Byun, Min Soo and Choi, Hye Ji and Kim, Yoon Hee and Gwag, Chung Hee and Oh, Yoonseok and Park, Jee Eun and Yi, Dahyun and others},
  title   = {{Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70875},
  pmid    = {41225766},
  url     = {https://doi.org/10.1002/alz.70875}
}

@article{xing2025-39780222,
  author  = {Xing, X. and Zhang, X. and Wang, K. and Wang, Z. and Feng, Y. and Li, X. and Hua, Y. and Zhang, L. and others},
  title   = {{Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database}},
  journal = {Alzheimer's research \& therapy},
  year    = {2025},
  doi     = {10.1186/s13195-024-01669-4},
  pmid    = {39780222},
  url     = {https://doi.org/10.1186/s13195-024-01669-4}
}

@article{kong2025-40520157,
  author  = {Kong, L. and Yang, X. and Xu, J.},
  title   = {{Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1593989},
  pmid    = {40520157},
  url     = {https://doi.org/10.3389/fphar.2025.1593989}
}

@article{leng2026-41396015,
  author  = {Leng, L. and Liao, Z. and Lu, P. and Sun, Y. and Weng, Q. and Fan, W. and Zhu, H. and Wu, W. and others},
  title   = {{Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2026},
  doi     = {10.1177/13872877251406619},
  pmid    = {41396015},
  url     = {https://doi.org/10.1177/13872877251406619}
}

@article{chen2025-40189473,
  author  = {Chen, Christopher and Katayama, Sadao and Lee, Jae Hong and Lee, Jun-Young and Nakagawa, Masaki and Torii, Kentaro and Ogawa, Tomoo and Dash, Amitabh and others},
  title   = {{Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100160},
  pmid    = {40189473},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100160}
}

@article{nadeau2024-38484213,
  author  = {Nadeau, S. E.},
  title   = {{Lecanemab Questions}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000209320},
  pmid    = {38484213},
  url     = {https://doi.org/10.1212/wnl.0000000000209320}
}

@article{molinahenry2025-40861822,
  author  = {Molina-Henry, Doris P and Raman, Rema and Liu, Andy and Langford, Oliver and Braunstein, Joel B and Verghese, Philip B and Venkatesh, Venky and Dhadda, Shobha and others},
  title   = {{Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab}},
  journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
  year    = {2025},
  doi     = {10.1002/dad2.70164},
  pmid    = {40861822},
  url     = {https://doi.org/10.1002/dad2.70164}
}

@article{rohatgi2025-41038644,
  author  = {Rohatgi, Saurabh and Zhu, Shenghua and Calle, Esteban and Ford, Jeremy N. and Kozak, Benjamin M. and Chagui, Odette Ganem and Vejdani‐Jahromi, Maryam and Griffin, Harry R. and others},
  title   = {{Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?}},
  journal = {American Journal of Neuroradiology},
  year    = {2025},
  doi     = {10.3174/ajnr.a8822},
  pmid    = {41038644},
  url     = {https://doi.org/10.3174/ajnr.a8822}
}

@article{kenichiro2025-41114448,
  author  = {Kenichiro, Sato and Yoshiki, Niimi and Ryoko, Ihara and Atsushi, Iwata and Kiyotaka, Nemoto and Tetsuaki, Arai and Shinji, Higashi and Ataru, Igarashi and others},
  title   = {{Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70652},
  pmid    = {41114448},
  url     = {https://doi.org/10.1002/alz.70652}
}

@article{yeon2025-40696527,
  author  = {Yeon, Jeon So and Sheng-Min, Wang and Woong, Roh Hyun and You, Kim Keun and Young, Chang Yoon and Eosu, Kim and Jae-Nam, Bae and Seung-Ho, Ryu},
  title   = {{Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab}},
  journal = {Journal of Korean medical science},
  year    = {2025},
  doi     = {10.3346/jkms.2025.40.e215},
  pmid    = {40696527},
  url     = {https://doi.org/10.3346/jkms.2025.40.e215}
}

@article{liao2026-41823189,
  author  = {Liao, Wang and Yu, Qun and Chen, Bin and Chen, Hualin and Zou, Liangyu and Xie, Haiqun and Chen, Haobo and Wang, Chenyang and others},
  title   = {{Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2026},
  doi     = {10.1002/alz.71231},
  pmid    = {41823189},
  url     = {https://doi.org/10.1002/alz.71231}
}

@article{majid2024-39207112,
  author  = {Majid, O. and Cao, Y. and Willis, B. A. and Hayato, S. and Takenaka, O. and Lalovic, B. and Sreerama Reddy, S. H. and Penner, N. and others},
  title   = {{Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease}},
  journal = {CPT: pharmacometrics \& systems pharmacology},
  year    = {2024},
  doi     = {10.1002/psp4.13224},
  pmid    = {39207112},
  url     = {https://doi.org/10.1002/psp4.13224}
}

@article{albertini2026-41286448,
  author  = {Albertini, G. and Zielonka, M. and Cuypers, M. L. and Snellinx, A. and Xu, C. and Poovathingal, S. and Wojno, M. and Davie, K. and van Lieshout, V. and Craessaerts, K. and Wolfs, L. and Pasciuto, E. and others},
  title   = {{The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia}},
  journal = {Nature Neuroscience},
  year    = {2026},
  doi     = {10.1038/s41593-025-02125-8},
  pmid    = {41286448},
  url     = {https://doi.org/10.1038/s41593-025-02125-8}
}

@article{johnson2026-41617706,
  author  = {Johnson, L. A. and Saito, K. and Pallerla, A. V. and Funnell, J. L. and Ezzo, A. R. and Song, C. M. and Harrison, D. A. and Norton, N. J. and Moore, L. C. and Van Eldik, L. J. and others},
  title   = {{Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA}},
  journal = {Nature Communications},
  year    = {2026},
  doi     = {10.1038/s41467-026-68921-3},
  pmid    = {41617706},
  url     = {https://doi.org/10.1038/s41467-026-68921-3}
}

@article{liu2024-39158850,
  author  = {Liu, L. and Saba, A. and Pascual, JR. and Miller, M. B. and Hennessey, E. L. and Lott, I. T. and Brickman, A. M. and Wilcock, D. M. and others},
  title   = {{Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome}},
  journal = {JAMA neurology},
  year    = {2024},
  doi     = {10.1001/jamaneurol.2024.2579},
  pmid    = {39158850},
  url     = {https://doi.org/10.1001/jamaneurol.2024.2579}
}

@article{gibson2024-39215494,
  author  = {Gibson, A. W. and Elser, H. and Rosso, M. and Cornblath, E. J. and Fonkeu, Y. and Prasad, S. and Rothstein, A. and Nasrallah, I. M. and others},
  title   = {{Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2024},
  doi     = {10.1002/alz.14223},
  pmid    = {39215494},
  url     = {https://doi.org/10.1002/alz.14223}
}

@article{yan2025-40242445,
  author  = {Yan, L. and Zhang, L. and Xu, Z. and Luo, Z.},
  title   = {{A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1559447},
  pmid    = {40242445},
  url     = {https://doi.org/10.3389/fphar.2025.1559447}
}

@article{shields2024-39559868,
  author  = {Shields, L. B. E. and Hust, H. and Cooley, S. D. and Cooper, G. E. and Hart, R. N. and Dennis, B. C. and Freeman, S. W. and Cain, J. F. and others},
  title   = {{Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.159},
  pmid    = {39559868},
  url     = {https://doi.org/10.14283/jpad.2024.159}
}

@article{jiang2026-41694525,
  author  = {Jiang, Xiangxiang and Lv, Gang and Mendes, Morgan E and Wu, Jun and Yuan, Jing and Lu, Z Kevin},
  title   = {{Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease}},
  journal = {Frontiers in public health},
  year    = {2026},
  doi     = {10.3389/fpubh.2026.1692508},
  pmid    = {41694525},
  url     = {https://doi.org/10.3389/fpubh.2026.1692508}
}

@article{mu2026-42785333,
  author  = {Mu, Rui and Hofmann, Anna and Gong, Katherine and Liu, Menghan and Roussak, Alex and Lowery, Joseph and Chen, Yike and Paczynski, Madeline and others},
  title   = {{Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study}},
  journal = {The Lancet Neurology},
  year    = {2026},
  doi     = {10.1016/s1474-4422(26)00284-x},
  pmid    = {42785333},
  url     = {https://doi.org/10.1016/s1474-4422(26)00284-x}
}

@article{cummings2023-37357276,
  author  = {Cummings, Jeffrey L. and Apostolova, L and Rabinovici, Gil D. and Atri, A and Aisen, Pau and Greenberg, S and Hendrix, S and Selkoe, D and Weiner, M and Petersen, R.C. and Salloway, Stephen},
  title   = {{Lecanemab: Appropriate Use Recommendations}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2023},
  doi     = {10.14283/jpad.2023.30},
  pmid    = {37357276},
  url     = {https://doi.org/10.14283/jpad.2023.30}
}

@article{zhou2025-40372759,
  author  = {Zhou, Frank F. and Essien, Utibe R. and Souza, Jeffrey M. and Sarkisian, Catherine A. and Damberg, Cheryl L. and Landon, Bruce E. and Mafi, John N.},
  title   = {{Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries}},
  journal = {JAMA Network Open},
  year    = {2025},
  doi     = {10.1001/jamanetworkopen.2025.11711},
  pmid    = {40372759},
  url     = {https://doi.org/10.1001/jamanetworkopen.2025.11711}
}

@article{ji2024-39702440,
  author  = {Ji, S. and Rosenbloom, M.},
  title   = {{Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01640-3},
  pmid    = {39702440},
  url     = {https://doi.org/10.1186/s13195-024-01640-3}
}

@article{hu2025-40290431,
  author  = {Hu, H. and Zhao, Y. and Mao, J. and He, J. and Zhang, Y. and Ye, H. and Yang, X.},
  title   = {{A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases}},
  journal = {Frontiers in pharmacology},
  year    = {2025},
  doi     = {10.3389/fphar.2025.1561020},
  pmid    = {40290431},
  url     = {https://doi.org/10.3389/fphar.2025.1561020}
}

@article{wang2025-40624486,
  author  = {Wang, Y. and Yu, Q. and Chen, B. and Zhou, J. and Li, Z. and Liao, W. and Liu, J. and Yang, A.},
  title   = {{Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review}},
  journal = {BMC neurology},
  year    = {2025},
  doi     = {10.1186/s12883-025-04302-5},
  pmid    = {40624486},
  url     = {https://doi.org/10.1186/s12883-025-04302-5}
}

@article{zhou2025-41447712,
  author  = {Zhou, Jin and Andreozzi, Erica M. and Llibre‐Guerra, Jorge J. and Clifford, David B. and Li, David and Wang, Guoqiao and Schneider, Lon S. S. and McDade, Eric and others},
  title   = {{Safety of Lecanemab After 6‐Month Treatment in the DIAN‐TU‐001 Trial}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_105304},
  pmid    = {41447712},
  url     = {https://doi.org/10.1002/alz70859_105304}
}

@article{xia2025-40730714,
  author  = {Xia, X. and Aye, S. and Frisell, O. and Aho, E. and Handels, R. and Li, Y. and Wimo, A. and Winblad, B. and Eriksdotter, M. and Skillbäck, T. B. and Kern, S. and Zetterberg, H. and others},
  title   = {{The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden}},
  journal = {PharmacoEconomics},
  year    = {2025},
  doi     = {10.1007/s40273-025-01527-7},
  pmid    = {40730714},
  url     = {https://doi.org/10.1007/s40273-025-01527-7}
}

@article{wildsmith2025-41447716,
  author  = {Wildsmith, Kristin R. and Charil, Arnaud and Benzinger, Tammie L.S. and Gordon, Brian Andrew and Bhagunde, Pratik R. and Li, David and Wang, Guoqiao and Reyderman, Larisa and others},
  title   = {{Lecanemab in DIAD: 6‐Month Amyloid PET Results from the DIAN‐TU‐001 Trial}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_105303},
  pmid    = {41447716},
  url     = {https://doi.org/10.1002/alz70859_105303}
}

@article{mao2026-41520099,
  author  = {Mao, Chenhui and Wang, Wenjun and Huang, Xinying and Wu, Meiqi and Wang, Yifei and Wang, Tianyi and Qiu, Yuyue and Chu, Shanshan and others},
  title   = {{Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution}},
  journal = {Alzheimer s Research \& Therapy},
  year    = {2026},
  doi     = {10.1186/s13195-025-01943-z},
  pmid    = {41520099},
  url     = {https://doi.org/10.1186/s13195-025-01943-z}
}

@article{qudoos2026-41966037,
  author  = {Qudoos, Muhammad A and Elliott, David P},
  title   = {{Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges}},
  journal = {The Senior care pharmacist},
  year    = {2026},
  doi     = {10.4140/tcp.n.2026.98},
  pmid    = {41966037},
  url     = {https://doi.org/10.4140/tcp.n.2026.98}
}

@article{knopman2023-36948153,
  author  = {Knopman, D. S.},
  title   = {{Lecanemab reduces brain amyloid-β and delays cognitive worsening}},
  journal = {Cell reports. Medicine},
  year    = {2023},
  doi     = {10.1016/j.xcrm.2023.100982},
  pmid    = {36948153},
  url     = {https://doi.org/10.1016/j.xcrm.2023.100982}
}

@article{vitek2023-36749830,
  author  = {Vitek, G. E. and Decourt, B. and Sabbagh, M. N.},
  title   = {{Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease}},
  journal = {Expert opinion on investigational drugs},
  year    = {2023},
  doi     = {10.1080/13543784.2023.2178414},
  pmid    = {36749830},
  url     = {https://doi.org/10.1080/13543784.2023.2178414}
}

@article{demr2026-42784125,
  author  = {Demır, Ülkü Figen and Dilbaz, Fatmanur Karakuş},
  title   = {{Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab}},
  journal = {Neurology International},
  year    = {2026},
  doi     = {10.3390/neurolint18090171},
  pmid    = {42784125},
  url     = {https://doi.org/10.3390/neurolint18090171}
}

@article{smith2025-39893139,
  author  = {Smith, Eric Edward and Phillips, Natalie A. and Feldman, Howard and BORRIE, MICHAEL J. and Ganesh, Aravind and Henri‐Bhargava, Alexandre and Desmarais, Philippe and Frank, Andrew and others},
  title   = {{Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100068},
  pmid    = {39893139},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100068}
}

@article{honig2023-36949897,
  author  = {Honig, L. S. and Barakos, J. and Dhadda, S. and Kanekiyo, M. and Reyderman, L. and Irizarry, M. and Kramer, L. D. and Swanson, C. J. and others},
  title   = {{ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2023},
  doi     = {10.1002/trc2.12377},
  pmid    = {36949897},
  url     = {https://doi.org/10.1002/trc2.12377}
}

@article{guizzaro2026-41852829,
  author  = {Guizzaro, L. and Bałkowiec-Iskra, E. and Haberkamp, M. and Mol, P. G. M. and Moreau, A. and Mueller-Berghaus, J. and Philadelphy, D. and Balabanov, P. and others},
  title   = {{Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab}},
  journal = {The Lancet regional health. Europe},
  year    = {2026},
  doi     = {10.1016/j.lanepe.2026.101644},
  pmid    = {41852829},
  url     = {https://doi.org/10.1016/j.lanepe.2026.101644}
}

@article{noh2026-42676462,
  author  = {Noh, M. Y. and Sung, W. and Kim, H. and Son, B. and Kim, Y. E. and Choi, Y. Y. and Holtzman, D. M. and Kim, S. H.},
  title   = {{Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers}},
  journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
  year    = {2026},
  doi     = {10.1002/dad2.70468},
  pmid    = {42676462},
  url     = {https://doi.org/10.1002/dad2.70468}
}

@article{park2024-38095619,
  author  = {Park, J. and Simpson, C. and Patel, K.},
  title   = {{Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease}},
  journal = {The Annals of pharmacotherapy},
  year    = {2024},
  doi     = {10.1177/10600280231218253},
  pmid    = {38095619},
  url     = {https://doi.org/10.1177/10600280231218253}
}

@article{sharma2025-08ace6f7,
  author  = {Sharma, Geetika},
  title   = {{Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada}},
  journal = {International Journal of Science and Research Archive},
  year    = {2025},
  doi     = {10.5281/zenodo.17615266},
  url     = {https://doi.org/10.5281/zenodo.17615266}
}

@article{kang2025-41069006,
  author  = {Kang, Wenyan and Gao, Chao and Li, Xiaoyan and Wang, Xiaoxue and Zhong, Huizhu and Wei, Qiao and Tang, Yonghua and Huang, Peijian and others},
  title   = {{Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer’s disease: Evidence from a multidimensional real-world study}},
  journal = {Chinese Medical Journal},
  year    = {2025},
  doi     = {10.1097/cm9.0000000000003888},
  pmid    = {41069006},
  url     = {https://doi.org/10.1097/cm9.0000000000003888}
}

@article{villain2025-40011173,
  author  = {Villain, N. and Planche, V. and Lilamand, M. and Cordonnier, C. and Soto-Martin, M. and Mollion, H. and Bombois, S. and Delrieu, J. and others},
  title   = {{Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100094},
  pmid    = {40011173},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100094}
}

@article{bobbins2025-40051090,
  author  = {Bobbins, A. and Davies, M. and Lynn, E. and Roy, D. and Yeomans, A. and Shakir, S. A. W.},
  title   = {{Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective}},
  journal = {British journal of clinical pharmacology},
  year    = {2025},
  doi     = {10.1002/bcp.70021},
  pmid    = {40051090},
  url     = {https://doi.org/10.1002/bcp.70021}
}

@article{park2024-39512702,
  author  = {Park, K. H. and Kim, G. H. and Kim, C. H. and Koh, S. H. and Moon, S. Y. and Park, Y. H. and Seo, S. W. and Yoon, B. and others},
  title   = {{Lecanemab: Appropriate Use Recommendations by Korean Dementia Association}},
  journal = {Dementia and neurocognitive disorders},
  year    = {2024},
  doi     = {10.12779/dnd.2024.23.4.165},
  pmid    = {39512702},
  url     = {https://doi.org/10.12779/dnd.2024.23.4.165}
}

@article{yoon2024-38779110,
  author  = {Yoon, C. H. and Groff, C. and Criss, O.},
  title   = {{Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease}},
  journal = {Innovations in pharmacy},
  year    = {2024},
  doi     = {10.24926/iip.v15i1.5787},
  pmid    = {38779110},
  url     = {https://doi.org/10.24926/iip.v15i1.5787}
}

@article{mummery2026-41390238,
  author  = {Mummery, Catherine J and Rasmussen, Jill and Blackburn, Dan and Coulthard, Elizabeth and Davies, R Rhys and Dorsey, Rachel and Fox, Nick C and Hosseini, Akram A and others},
  title   = {{Lecanemab appropriate use recommendations for clinical practice in the UK}},
  journal = {Journal of neurology, neurosurgery, and psychiatry},
  year    = {2026},
  doi     = {10.1136/jnnp-2025-336597},
  pmid    = {41390238},
  url     = {https://doi.org/10.1136/jnnp-2025-336597}
}

@article{solfrizzi2026-41428477,
  author  = {Solfrizzi, Vincenzo and Imbimbo, Bruno P},
  title   = {{Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2026},
  doi     = {10.1177/13872877251406221},
  pmid    = {41428477},
  url     = {https://doi.org/10.1177/13872877251406221}
}

@article{xiaojuan2025-41139687,
  author  = {Xiaojuan, Li and Sonal, Singh and Andrea, DeVries and Gurwitz Jerry, H.},
  title   = {{Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2025},
  doi     = {10.1111/jgs.70010},
  pmid    = {41139687},
  url     = {https://doi.org/10.1111/jgs.70010}
}

@article{soderberg2023-36253511,
  author  = {Söderberg, L. and Johannesson, M. and Nygren, P. and Laudon, H. and Eriksson, F. and Osswald, G. and Möller, C. and Lannfelt, L.},
  title   = {{Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2023},
  doi     = {10.1007/s13311-022-01308-6},
  pmid    = {36253511},
  url     = {https://doi.org/10.1007/s13311-022-01308-6}
}

@article{shi2022-35493943,
  author  = {Shi, M. and Chu, F. and Zhu, F. and Zhu, J.},
  title   = {{Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab}},
  journal = {Frontiers in aging neuroscience},
  year    = {2022},
  doi     = {10.3389/fnagi.2022.870517},
  pmid    = {35493943},
  url     = {https://doi.org/10.3389/fnagi.2022.870517}
}

@article{tampi2025-40078953,
  author  = {Tampi, Rajesh R},
  title   = {{Lecanemab for mild Alzheimer disease - is there a way forward?}},
  journal = {Drugs in context},
  year    = {2025},
  doi     = {10.7573/dic.2024-12-2},
  pmid    = {40078953},
  url     = {https://doi.org/10.7573/dic.2024-12-2}
}

@article{arai2025-40708311,
  author  = {Arai, Heii and Aiba, Satoko and Arai, Reiko},
  title   = {{Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2025},
  doi     = {10.1177/13872877251361051},
  pmid    = {40708311},
  url     = {https://doi.org/10.1177/13872877251361051}
}

@article{kaur2024-38095822,
  author  = {Kaur, Upinder and Reddy, Jaideep and Tiwari, Ashutosh and Chakrabarti, Sasanka and Chakrabarti, Sankha Shubhra},
  title   = {{Lecanemab: More Questions Than Answers!}},
  journal = {Clinical drug investigation},
  year    = {2024},
  doi     = {10.1007/s40261-023-01331-1},
  pmid    = {38095822},
  url     = {https://doi.org/10.1007/s40261-023-01331-1}
}

@article{niidome2024-38692883,
  author  = {Niidome, Tetsuhiro and Ishikawa, Yukio and Ogawa, Tomoo and Nakagawa, Masaki and Nakamura, Yosuke},
  title   = {{[Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer's disease]}},
  journal = {Nihon yakurigaku zasshi. Folia pharmacologica Japonica},
  year    = {2024},
  doi     = {10.1254/fpj.24005},
  pmid    = {38692883},
  url     = {https://doi.org/10.1254/fpj.24005}
}

@article{liu2026-42746606,
  author  = {Liu, Andy and Moghadam, Alexander A. and Alam, Mohammad Samsul and Lutz, Michael William and Navarra, Amber and Luo, Sheng and Wang, Li and Petrella, Jeffrey R. and others},
  title   = {{Clinical Practice Outcomes With Lecanemab for Alzheimer Disease}},
  journal = {Neurology Open Access},
  year    = {2026},
  doi     = {10.1212/wn9.0000000000000121},
  pmid    = {42746606},
  url     = {https://doi.org/10.1212/wn9.0000000000000121}
}

@article{rotela2026-ee62b24d,
  author  = {Rotela, Lorena Guadalupe Delvalle and Olmedo, Katherinne Ailen Sanchez},
  title   = {{Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.22756413},
  url     = {https://doi.org/10.5281/zenodo.22756413}
}

@article{bryan2025-40895811,
  author  = {Bryan, Tysinger and Yifan, Wei and Hanke, Heun-Johnson and Zissimopoulos Julie, M.},
  title   = {{Long-term value of lecanemab to individuals and families}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2025},
  doi     = {10.1002/trc2.70151},
  pmid    = {40895811},
  url     = {https://doi.org/10.1002/trc2.70151}
}

@article{espay2024-38701151,
  author  = {Espay, A. J. and Herrup, K. and Imbimbo, B. P. and Kepp, K. P. and Daly, T.},
  title   = {{Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240171},
  pmid    = {38701151},
  url     = {https://doi.org/10.3233/jad-240171}
}

@article{kurkinen2023-37676096,
  author  = {Kurkinen, Markku},
  title   = {{Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease}},
  journal = {Advances in clinical and experimental medicine : official organ Wroclaw Medical University},
  year    = {2023},
  doi     = {10.17219/acem/171379},
  pmid    = {37676096},
  url     = {https://doi.org/10.17219/acem/171379}
}

@article{chowdhury2023-39726673,
  author  = {Chowdhury, Selia},
  title   = {{Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab}},
  journal = {Discoveries (Craiova, Romania)},
  year    = {2023},
  doi     = {10.15190/d.2023.12},
  pmid    = {39726673},
  url     = {https://doi.org/10.15190/d.2023.12}
}

@article{jonsson2023-37251789,
  author  = {Jönsson, Linus and Wimo, Anders and Handels, Ron and Johansson, Gunilla and Boada, Mercè and Engelborghs, Sebastiaan and Frölich, Lutz and Jessen, Frank and others},
  title   = {{The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint}},
  journal = {The Lancet regional health. Europe},
  year    = {2023},
  doi     = {10.1016/j.lanepe.2023.100657},
  pmid    = {37251789},
  url     = {https://doi.org/10.1016/j.lanepe.2023.100657}
}

@article{kepp2023-37334596,
  author  = {Kepp, Kasper P and Sensi, Stefano L and Johnsen, Kasper B and Barrio, Jorge R and Høilund-Carlsen, Poul F and Neve, Rachael L and Alavi, Abass and Herrup, Karl and others},
  title   = {{The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2023},
  doi     = {10.3233/jad-230099},
  pmid    = {37334596},
  url     = {https://doi.org/10.3233/jad-230099}
}

@article{zhang2023-37682322,
  author  = {Zhang, Jinwei},
  title   = {{Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment}},
  journal = {Inflammation research : official journal of the European Histamine Research Society ... [et al.]},
  year    = {2023},
  doi     = {10.1007/s00011-023-01788-y},
  pmid    = {37682322},
  url     = {https://doi.org/10.1007/s00011-023-01788-y}
}

@article{hoy2023-36856953,
  author  = {Hoy, S. M.},
  title   = {{Lecanemab: First Approval}},
  journal = {Drugs},
  year    = {2023},
  doi     = {10.1007/s40265-023-01851-2},
  pmid    = {36856953},
  url     = {https://doi.org/10.1007/s40265-023-01851-2}
}

@article{monfared2025-41433980,
  author  = {Monfared, Amir Abbas Tahami and Zhang, Raymond J. and Zhang, Quanwu and Gao, Ran and Haji, Babak},
  title   = {{Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee‐for‐service beneficiaries}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70860_106870},
  pmid    = {41433980},
  url     = {https://doi.org/10.1002/alz70860_106870}
}

@article{han2025-cbaaba6e,
  author  = {Han, Jayoung and Fang, Yuan and Campbell, Nicole},
  title   = {{Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system}},
  journal = {JAPhA Pharmacotherapy},
  year    = {2025},
  doi     = {10.1016/j.japhar.2025.100015},
  url     = {https://doi.org/10.1016/j.japhar.2025.100015}
}

@article{igarashi2026-42108615,
  author  = {Igarashi, A. and Azuma-Kasai, M. and Tani, M. and Utsumi, T. and Shibahara, H. and Inoue, S. and Rothwell, S. and Kamanaka, G. and Sakata, Y. and Hiyoshi, H. and Tomita, K.},
  title   = {{The social value of lecanemab for patients with early Alzheimer's disease in Japan}},
  journal = {Journal of Alzheimer's Disease},
  year    = {2026},
  doi     = {10.1177/13872877261447312},
  pmid    = {42108615},
  url     = {https://doi.org/10.1177/13872877261447312}
}

@article{weiss2026-42373113,
  author  = {Weiss, Sophie M. and Watt, Jennifer A. and Ewa, Vivian and Straus, Sharon Elizabeth},
  title   = {{Lecanemab use for early Alzheimer disease in Canada}},
  journal = {Canadian Medical Association Journal},
  year    = {2026},
  doi     = {10.1503/cmaj.260193},
  pmid    = {42373113},
  url     = {https://doi.org/10.1503/cmaj.260193}
}

@article{hyemin2026-42449395,
  author  = {Hyemin, Jang and Woo, Kim Jae and Won, Hwang Jung and Da Woon, Jeong and Jeongeun, Ka and Da Min, Kang and Hyun, Suh Chong and Yangsean, Choi and others},
  title   = {{Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experience}},
  journal = {Alzheimer's research \& therapy},
  year    = {2026},
  doi     = {10.1186/s13195-026-02141-1},
  pmid    = {42449395},
  url     = {https://doi.org/10.1186/s13195-026-02141-1}
}

@article{stern2025-41435407,
  author  = {Stern, Andrew M. and Francis, Anna G. and Meunier, Angela L. and Anderson, Amirah K. and Hennessey, Elizabeth L. and Miller, Michael B. and Lemere, Cynthia Ann and Selkoe, Dennis J.},
  title   = {{Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopes}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70855_099914},
  pmid    = {41435407},
  url     = {https://doi.org/10.1002/alz70855_099914}
}

@article{donati2025-40217276,
  author  = {Donati, Monia and Boccia, Angelo Sabato and De Ponti, Fabrizio and Poluzzi, Elisabetta and Raschi, Emanuel},
  title   = {{Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance}},
  journal = {Alzheimer s Research \& Therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01699-6},
  pmid    = {40217276},
  url     = {https://doi.org/10.1186/s13195-025-01699-6}
}

@article{reyes2025-40495448,
  author  = {Reyes, Fernanda S. Peralta and Sommerhage, Simon and Willbold, Dieter and Schröder, Gunnar F. and Gremer, Lothar},
  title   = {{Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds}},
  journal = {Neuropathology and Applied Neurobiology},
  year    = {2025},
  doi     = {10.1111/nan.70022},
  pmid    = {40495448},
  url     = {https://doi.org/10.1111/nan.70022}
}

@article{sha2026-42368154,
  author  = {Sha, Jiaojiao and Geng, Zijin and Qi, Shanyu and Du, Liangjia and Hu, Qianqian and Cai, Minqi and Chen, Dezhu and Chen, Yuehua and others},
  title   = {{Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry}},
  journal = {ACS Omega},
  year    = {2026},
  doi     = {10.1021/acsomega.6c02666},
  pmid    = {42368154},
  url     = {https://doi.org/10.1021/acsomega.6c02666}
}

@article{hansen2025-41052542,
  author  = {Hansen, Niels and Wiltfang, Jens},
  title   = {{Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-Demenz}},
  journal = {Fortschritte der Neurologie · Psychiatrie},
  year    = {2025},
  doi     = {10.1055/a-2681-4558},
  pmid    = {41052542},
  url     = {https://doi.org/10.1055/a-2681-4558}
}

@article{schwartz2025-40584633,
  author  = {Schwartz, Nicholas U. and Dietz, Connor D. and Araújo, Igor Prufer and Villanueva-Meyer, Javier E. and Chiong, Winston and Lane‐Donovan, Courtney and VandeVrede, Lawren A. and Ljubenkov, Peter Alexander and others},
  title   = {{Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease}},
  journal = {Neurology Clinical Practice},
  year    = {2025},
  doi     = {10.1212/cpj.0000000000200508},
  pmid    = {40584633},
  url     = {https://doi.org/10.1212/cpj.0000000000200508}
}

@article{ameen2025-2abd646d,
  author  = {Ameen, Taha Basit and Ali, Umair and Salma, Omme and Samee, Muhammad Abdul and Abbas, Syed Muhammad Iraj and Kashif, Syeda Naveera and Arifi, Muhammad Arif and Ali, Mashooque and others},
  title   = {{Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease}},
  journal = {The Egyptian Journal of Neurology Psychiatry and Neurosurgery},
  year    = {2025},
  doi     = {10.1186/s41983-025-00968-3},
  url     = {https://doi.org/10.1186/s41983-025-00968-3}
}

@article{sharma2025-d453d052,
  author  = {Sharma, Geetika},
  title   = {{Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada}},
  journal = {International Journal of Science and Research Archive},
  year    = {2025},
  doi     = {10.5281/zenodo.17615265},
  url     = {https://doi.org/10.5281/zenodo.17615265}
}

@article{sharma2025-1b2f6657,
  author  = {Sharma, Geetika},
  title   = {{Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada}},
  journal = {International Journal of Science and Research Archive},
  year    = {2025},
  doi     = {10.30574/ijsra.2025.17.1.2929},
  url     = {https://doi.org/10.30574/ijsra.2025.17.1.2929}
}

@article{bombonalban2025-ab04d0ab,
  author  = {Bombón-Albán, Paulina Elizabeth and Salazar, Johanna Vanessa Suárez and León, Lennyn Albán},
  title   = {{Lecanemab en la enfermedad de Alzheimer}},
  journal = {Acta neurológica colombiana},
  year    = {2025},
  doi     = {10.22379/anc.v41i2.1938},
  url     = {https://doi.org/10.22379/anc.v41i2.1938}
}

@article{tan2025-40955711,
  author  = {Tan, Arui and Wang, Zuxing and Aumont, Étienne and Li, Aonan and Qin, Xiaohong and Yang, Xinxuan and Feng, Wenqian and Yang, Jianwei and others},
  title   = {{Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China}},
  journal = {Alzheimer Disease \& Associated Disorders},
  year    = {2025},
  doi     = {10.1097/wad.0000000000000689},
  pmid    = {40955711},
  url     = {https://doi.org/10.1097/wad.0000000000000689}
}

@article{nonino2025-40637522,
  author  = {Nonino, Francesco and Colosimo, Carlo and Massacesi, Luca},
  title   = {{Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie}},
  journal = {Recenti Progressi in Medicina},
  year    = {2025},
  doi     = {10.1701/4530.45309},
  pmid    = {40637522},
  url     = {https://doi.org/10.1701/4530.45309}
}

@article{dinnerstein2026-41773886,
  author  = {Dinnerstein, Eric},
  title   = {{Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together}},
  journal = {Alzheimer Disease \& Associated Disorders},
  year    = {2026},
  doi     = {10.1097/wad.0000000000000711},
  pmid    = {41773886},
  url     = {https://doi.org/10.1097/wad.0000000000000711}
}

@article{cdaamc2026-25dfc5ad,
  author  = {CDA-AMC},
  title   = {{Lecanemab (Leqembi)}},
  journal = {Canadian Journal of Health Technologies},
  year    = {2026},
  doi     = {10.51731/cjht.2026.1514},
  url     = {https://doi.org/10.51731/cjht.2026.1514}
}

@article{rotela2026-cf778e0b,
  author  = {Rotela, Lorena Guadalupe Delvalle and Olmedo, Katherinne Ailen Sanchez},
  title   = {{Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.22756412},
  url     = {https://doi.org/10.5281/zenodo.22756412}
}

@article{duran2025-d42e1b7d,
  author  = {Durán, Stephanie Hernández and Ceja, Militza Jakeline Gómez},
  title   = {{Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer}},
  journal = {Acta Médica Grupo Ángeles},
  year    = {2025},
  doi     = {10.35366/119479},
  url     = {https://doi.org/10.35366/119479}
}

@article{sanz2025-d2104574,
  author  = {Sanz, Mercedes},
  title   = {{Lecanemab autorizado para tratamiento del Alzhéimer en pacientes que tienen una o ninguna copia de ApoE4: una reacción adversa grave limita su uso}},
  journal = {Panorama actual del medicamento},
  year    = {2025},
  doi     = {10.63105/pam8},
  url     = {https://doi.org/10.63105/pam8}
}

@article{study2026-b85e6325,
  title   = {{Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab}},
  journal = {Neuroradiologie Scan},
  year    = {2026},
  doi     = {10.1055/a-2788-0873},
  url     = {https://doi.org/10.1055/a-2788-0873}
}

@article{nossler2025-52ec276c,
  author  = {Nößler, Denis and Scherer, Martin and Duning, Thomas},
  title   = {{Transkript zur Episode „Lecanemab“}},
  journal = {EvidenzUpdate},
  year    = {2025},
  doi     = {10.69156/trx.001/2025.10.00152},
  url     = {https://doi.org/10.69156/trx.001/2025.10.00152}
}

@article{study2026-0681bd63,
  title   = {{Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antikörpers}},
  journal = {Fortschritte der Neurologie · Psychiatrie},
  year    = {2026},
  doi     = {10.1055/a-2861-9919},
  url     = {https://doi.org/10.1055/a-2861-9919}
}

@article{study2025-eac9be64,
  title   = {{Lecanemab bei Alzheimer-Krankheit: Frühe Therapie ist sicher}},
  journal = {Fortschritte der Neurologie · Psychiatrie},
  year    = {2025},
  doi     = {10.1055/a-2700-9104},
  url     = {https://doi.org/10.1055/a-2700-9104}
}

@article{study2023-40d8b15f,
  title   = {{Lecanemab for Alzheimer's Disease: Effectiveness and Value — Final Evidence Report}},
  journal = {ICER (independent health technology assessment report)},
  year    = {2023}
}

@article{marciniakagra2026-1d9e787e,
  author  = {Marciniak-Agra, K. and Devi, G.},
  title   = {{Amyloid and Tau Cerebrospinal Fluid Biomarker Normalization in a Patient with Alzheimer’s Disease treated with Lecanemab: A Case Report}},
  journal = {Research Square},
  year    = {2026},
  doi     = {10.21203/rs.3.rs-10778388/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-10778388/v1}
}

@article{rezaii2026-4202aa20,
  author  = {Rezaii, N. and Dickson, JR. and Ford, J. N. and He, Y. and Katsumi, Y. and Ramirez-Gomez, L. and Lam, A. and Shah, H. and others},
  title   = {{Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System}},
  journal = {medRxiv},
  year    = {2026},
  doi     = {10.64898/2026.01.23.26344739},
  url     = {https://doi.org/10.64898/2026.01.23.26344739}
}

@article{curd2025-b62fc105,
  author  = {Curd, B. C. and Zubrick, C. and Cliatt Brown, C. J. and Sorweid, M. K. and Dehoney, S. B. and Anzai, Y. and Minoshima, S. and Parks, A. L. and others},
  title   = {{Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain West}},
  journal = {medRxiv},
  year    = {2025},
  doi     = {10.1101/2025.09.30.25337002},
  url     = {https://doi.org/10.1101/2025.09.30.25337002}
}

@article{study2023-149a0541,
  title   = {{FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease}},
  journal = {U.S. Food and Drug Administration (announced via Biogen press release)},
  year    = {2023}
}

@article{qiao2024-38429615,
  author  = {Qiao, Y. and Gu, J. and Yu, M. and Chi, Y. and Ma, Y.},
  title   = {{Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis}},
  journal = {CNS drugs},
  year    = {2024},
  doi     = {10.1007/s40263-024-01067-2},
  pmid    = {38429615},
  url     = {https://doi.org/10.1007/s40263-024-01067-2}
}

@article{hsu2025-40316479,
  author  = {Hsu, C. W. and Hsu, T. W. and Kao, Y. C. and Lin, Y. H. and Thompson, T. and Carvalho, A. F. and Stubbs, B. and Tseng, P. T. and others},
  title   = {{The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100195},
  pmid    = {40316479},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100195}
}

@article{wu2023-38017568,
  author  = {Wu, W. and Ji, Y. and Wang, Z. and Wu, X. and Li, J. and Gu, F. and Chen, Z.},
  title   = {{The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials}},
  journal = {European journal of medical research},
  year    = {2023},
  doi     = {10.1186/s40001-023-01512-w},
  pmid    = {38017568},
  url     = {https://doi.org/10.1186/s40001-023-01512-w}
}

@article{shim2026-41352683,
  author  = {Shim, G. H. and Lau, E. C. Y. and Huynh, A. L. H. and Lu, C. Y. and Tan, E. C. K.},
  title   = {{Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2026},
  doi     = {10.1016/j.arr.2025.102981},
  pmid    = {41352683},
  url     = {https://doi.org/10.1016/j.arr.2025.102981}
}

@article{jeremic2023-37423541,
  author  = {Jeremic, D. and Navarro-López, J. D. and Jiménez-Díaz, L.},
  title   = {{Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis}},
  journal = {Ageing research reviews},
  year    = {2023},
  doi     = {10.1016/j.arr.2023.102012},
  pmid    = {37423541},
  url     = {https://doi.org/10.1016/j.arr.2023.102012}
}

@article{ebell2024-38253509,
  author  = {Ebell, M. H. and Barry, H. C. and Baduni, K. and Grasso, G.},
  title   = {{Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis}},
  journal = {Annals of Family Medicine},
  year    = {2024},
  doi     = {10.1370/afm.3050},
  pmid    = {38253509},
  url     = {https://doi.org/10.1370/afm.3050}
}

@article{avgerinos2024-39468148,
  author  = {Avgerinos, K. I. and Manolopoulos, A. and Ferrucci, L. and Kapogiannis, D.},
  title   = {{Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness}},
  journal = {Scientific reports},
  year    = {2024},
  doi     = {10.1038/s41598-024-75204-8},
  pmid    = {39468148},
  url     = {https://doi.org/10.1038/s41598-024-75204-8}
}

@article{chundu2025-40621323,
  author  = {Chundu, U. C. and Thiriveedhi, SR. and Bhatti, C. and Mupparaju, J. S. and Otinashvili, N. and Gelishvili, E.},
  title   = {{A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease}},
  journal = {Cureus},
  year    = {2025},
  doi     = {10.7759/cureus.85377},
  pmid    = {40621323},
  url     = {https://doi.org/10.7759/cureus.85377}
}

@article{chhabra2024-39432414,
  author  = {Chhabra, Akanksha and Solanki, Siddhant and Saravanabawan, Prithvi and Venkiteswaran, Arun and Nimmathota, NagaTarang and Modi, Nishi Manojkumar},
  title   = {{A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2024},
  doi     = {10.1080/14712598.2024.2416947},
  pmid    = {39432414},
  url     = {https://doi.org/10.1080/14712598.2024.2416947}
}

@article{su2025-40473116,
  author  = {Su, Ching-Hui and Chang, Ying-Tzu and Tseng, Huan-Shu and Kuo, Chan-Yen and Chen, Jin-Hua and Chien, Po-Yu and Chang, Yao-Jen and Hung, Chin-Chuan},
  title   = {{Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials}},
  journal = {Clinical medicine (London, England)},
  year    = {2025},
  doi     = {10.1016/j.clinme.2025.100336},
  pmid    = {40473116},
  url     = {https://doi.org/10.1016/j.clinme.2025.100336}
}

@article{vanetten2026-912127c4,
  author  = {van Etten, E. S. and others},
  title   = {{Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup}},
  journal = {Alzheimer's \& Dementia},
  year    = {2026}
}

@article{wang2022-35320578,
  author  = {Wang, D. and Kowalewski, E. K. and Koch, G.},
  title   = {{Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease}},
  journal = {Therapeutic innovation \& regulatory science},
  year    = {2022},
  doi     = {10.1007/s43441-022-00390-4},
  pmid    = {35320578},
  url     = {https://doi.org/10.1007/s43441-022-00390-4}
}

@article{vanolst2025-40050704,
  author  = {van Olst, L. and Simonton, B. and Edwards, A. J. and Forsyth, A. V. and Boles, J. and Jamshidi, P. and Watson, T. and Shepard, N. and Krainc, T. and Argue, B. M. and Zhang, Z. and Kuruvilla, J. and others},
  title   = {{Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease}},
  journal = {Nature Medicine},
  year    = {2025},
  doi     = {10.1038/s41591-025-03574-1},
  pmid    = {40050704},
  url     = {https://doi.org/10.1038/s41591-025-03574-1}
}

@article{lista2024-39080712,
  author  = {Lista, S. and Imbimbo, B. P. and Grasso, M. and Fidilio, A. and Emanuele, E. and Minoretti, P. and López-Ortiz, S. and Martín-Hernández, J. and others},
  title   = {{Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?}},
  journal = {Journal of neuroinflammation},
  year    = {2024},
  doi     = {10.1186/s12974-024-03163-y},
  pmid    = {39080712},
  url     = {https://doi.org/10.1186/s12974-024-03163-y}
}

@article{pittock2023-37586881,
  author  = {Pittock, R. R. and Aakre, J. A. and Castillo, A. M. and Ramanan, V. K. and Kremers, W. K. and Jack, C. R. and Vemuri, P. and Lowe, V. J. and others},
  title   = {{Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207770},
  pmid    = {37586881},
  url     = {https://doi.org/10.1212/wnl.0000000000207770}
}

@article{barroeta2025-40528298,
  author  = {Barroeta, Isabel and Videla, Laura and Carmona‐Iragui, María and Fortea, Juan and Rafii, Michael S.},
  title   = {{Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70258},
  pmid    = {40528298},
  url     = {https://doi.org/10.1002/alz.70258}
}

@article{wolters2024-38380503,
  author  = {Wolters, Frank J and Labrecque, Jeremy A},
  title   = {{Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2024},
  doi     = {10.1002/alz.13690},
  pmid    = {38380503},
  url     = {https://doi.org/10.1002/alz.13690}
}

@article{cao2025-39550061,
  author  = {Cao, W. and Zhu, B. and Liu, Z. and Jia, X. and Zhao, H. and Gu, N. and Chang, H. and Xi, J. and others},
  title   = {{Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer 's disease: A systematic review and network meta- analysis}},
  journal = {Neuroscience},
  year    = {2025},
  doi     = {10.1016/j.neuroscience.2024.11.029},
  pmid    = {39550061},
  url     = {https://doi.org/10.1016/j.neuroscience.2024.11.029}
}

@article{huang2023-37784171,
  author  = {Huang, L. K. and Kuan, Y. C. and Lin, H. W. and Hu, C. J.},
  title   = {{Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update}},
  journal = {Journal of biomedical science},
  year    = {2023},
  doi     = {10.1186/s12929-023-00976-6},
  pmid    = {37784171},
  url     = {https://doi.org/10.1186/s12929-023-00976-6}
}

@article{hartz2025-39949872,
  author  = {Hartz, Sarah M. and Schindler, Suzanne Elizabeth and Streitz, Marissa L. and Moulder, Krista L. and Mozersky, Jessica T. and Wang, Guoqiao and Xiong, Chengjie and Morris, John C.},
  title   = {{Assessing the clinical meaningfulness of slowing CDR‐SB progression with disease‐modifying therapies for Alzheimer's disease}},
  journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year    = {2025},
  doi     = {10.1002/trc2.70033},
  pmid    = {39949872},
  url     = {https://doi.org/10.1002/trc2.70033}
}

@article{okonkwo2025-39760440,
  author  = {Okonkwo, Ozioma C. and Mindt, Mónica Rivera and Weiner, Michael Walter and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14186},
  pmid    = {39760440},
  url     = {https://doi.org/10.1002/alz.14186}
}

@article{withington2022-35401412,
  author  = {Withington, C. G. and Turner, R. S.},
  title   = {{Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease}},
  journal = {Frontiers in neurology},
  year    = {2022},
  doi     = {10.3389/fneur.2022.862369},
  pmid    = {35401412},
  url     = {https://doi.org/10.3389/fneur.2022.862369}
}

@article{hendriks2026-95d6b60f,
  author  = {Hendriks, J. and Antoniou, M. and Babic, I.},
  title   = {{Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.22310607},
  url     = {https://doi.org/10.5281/zenodo.22310607}
}

@article{rafii2023-35971310,
  author  = {Rafii, M. S. and Sperling, R. A. and Donohue, M. C. and Zhou, J. and Roberts, C. and Irizarry, M. C. and Dhadda, S. and Sethuraman, G. and others},
  title   = {{The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2023},
  doi     = {10.1002/alz.12748},
  pmid    = {35971310},
  url     = {https://doi.org/10.1002/alz.12748}
}

@article{rosenbloom2025-40355750,
  author  = {Rosenbloom, M. and Schnee, A. and Nimma, S. and Lutz, H. and Gzesh, D. and Weisman, D.},
  title   = {{Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics}},
  journal = {Journal of neurology},
  year    = {2025},
  doi     = {10.1007/s00415-025-13142-9},
  pmid    = {40355750},
  url     = {https://doi.org/10.1007/s00415-025-13142-9}
}

@article{debattista2024-38993656,
  author  = {DeBattista, C. and Schatzberg, A. F.},
  title   = {{The Black Book of Psychotropic Dosing and Monitoring}},
  journal = {Psychopharmacology bulletin},
  year    = {2024},
  doi     = {10.64719/pb.4493},
  pmid    = {38993656},
  url     = {https://doi.org/10.64719/pb.4493}
}

@article{jiang2026-41837605,
  author  = {Jiang, X. and Lv, G. and Xiong, X. and Yuan, J. and Kevin Lu, Z.},
  title   = {{Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review}},
  journal = {Journal of Alzheimer's Disease},
  year    = {2026},
  doi     = {10.1177/13872877261430376},
  pmid    = {41837605},
  url     = {https://doi.org/10.1177/13872877261430376}
}

@article{wu2025-40442885,
  author  = {Wu, Chuang‐Kuo and Fuh, Jong‐Ling},
  title   = {{A 2025 update on treatment strategies for the Alzheimer’s disease spectrum}},
  journal = {Journal of the Chinese Medical Association},
  year    = {2025},
  doi     = {10.1097/jcma.0000000000001252},
  pmid    = {40442885},
  url     = {https://doi.org/10.1097/jcma.0000000000001252}
}

@article{alvarado2024-38181731,
  author  = {Alvarado, C. X. and Makarious, M. B. and Weller, C. A. and Vitale, D. and Koretsky, M. J. and Bandres-Ciga, S. and Iwaki, H. and Levine, K. and others},
  title   = {{omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases}},
  journal = {American journal of human genetics},
  year    = {2024},
  doi     = {10.1016/j.ajhg.2023.12.006},
  pmid    = {38181731},
  url     = {https://doi.org/10.1016/j.ajhg.2023.12.006}
}

@article{soderberg2024-38740836,
  author  = {Söderberg, L. and Johannesson, M. and Gkanatsiou, E. and Nygren, P. and Fritz, N. and Zachrisson, O. and Rachalski, A. and Svensson, A. S. and others},
  title   = {{Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities}},
  journal = {Scientific reports},
  year    = {2024},
  doi     = {10.1038/s41598-024-61691-2},
  pmid    = {38740836},
  url     = {https://doi.org/10.1038/s41598-024-61691-2}
}

@article{geerts2024-38774587,
  author  = {Geerts, H. and Bergeler, S. and Walker, M. and Rose, R. H. and van der Graaf, P. H.},
  title   = {{Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2024},
  doi     = {10.1002/trc2.12474},
  pmid    = {38774587},
  url     = {https://doi.org/10.1002/trc2.12474}
}

@article{heneka2024-39549715,
  author  = {Heneka, Michael T and Morgan, David and Jessen, Frank},
  title   = {{Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges}},
  journal = {Lancet (London, England)},
  year    = {2024},
  doi     = {10.1016/s0140-6736(24)01883-x},
  pmid    = {39549715},
  url     = {https://doi.org/10.1016/s0140-6736(24)01883-x}
}

@article{hoilundcarlsen2023-37414156,
  author  = {Høilund-Carlsen, Poul F and Revheim, Mona-Elisabeth and Costa, Tommaso and Alavi, Abass and Kepp, Kasper P and Sensi, Stefano L and Perry, George and Robakis, Nikolaos K and others},
  title   = {{Passive Alzheimer's immunotherapy: A promising or uncertain option?}},
  journal = {Ageing research reviews},
  year    = {2023},
  doi     = {10.1016/j.arr.2023.101996},
  pmid    = {37414156},
  url     = {https://doi.org/10.1016/j.arr.2023.101996}
}

@article{vigneswaran2025-40506692,
  author  = {Vigneswaran, Sinthujah and Vijverberg, Everard G.B. and Barkhof, Frederik and van de Giessen, Elsmarieke and Lemstra, Afina Willemina and Pijnenburg, Yolande A.L. and Teunissen, Charlotte Elisabeth and van der Flier, Wiesje M. and others},
  title   = {{“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70375},
  pmid    = {40506692},
  url     = {https://doi.org/10.1002/alz.70375}
}

@article{filippi2026-41732200,
  author  = {Filippi, M. and Cecchetti, G. and Spinelli, E. G. and Ghirelli, A. and Rugarli, G. and Pisano, S. and Canu, E. and Agosta, F.},
  title   = {{Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline}},
  journal = {The Lancet regional health. Europe},
  year    = {2026},
  doi     = {10.1016/j.lanepe.2026.101609},
  pmid    = {41732200},
  url     = {https://doi.org/10.1016/j.lanepe.2026.101609}
}

@article{higgins2026-41596530,
  author  = {Higgins, M. and Wasef, V. and Kwakowsky, A.},
  title   = {{FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?}},
  journal = {International journal of molecular sciences},
  year    = {2026},
  doi     = {10.3390/ijms27020883},
  pmid    = {41596530},
  url     = {https://doi.org/10.3390/ijms27020883}
}

@article{weiner2025-39711072,
  author  = {Weiner, Michael W and Kanoria, Shaveta and Miller, Melanie J and Aisen, Paul S and Beckett, Laurel A and Conti, Catherine and Diaz, Adam and Flenniken, Derek and others},
  title   = {{Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.14321},
  pmid    = {39711072},
  url     = {https://doi.org/10.1002/alz.14321}
}

@article{hardy2024-38165303,
  author  = {Hardy, John and Schott, Jonathan M},
  title   = {{Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000208096},
  pmid    = {38165303},
  url     = {https://doi.org/10.1212/wnl.0000000000208096}
}

@article{castellani2023-37125554,
  author  = {Castellani, Rudolph J and Shanes, Elisheva D and McCord, Matthew and Reish, Nicholas J and Flanagan, Margaret E and Mesulam, M-Marsel and Jamshidi, Pouya},
  title   = {{Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2023},
  doi     = {10.3233/jad-221305},
  pmid    = {37125554},
  url     = {https://doi.org/10.3233/jad-221305}
}

@article{wongsodirdjo2024-38585667,
  author  = {Wongsodirdjo, Patricia and Caruso, Alayna C and Yong, Alicia K and Lester, Madeleine A and Vella, Laura J and Hung, Ya Hui and Nisbet, Rebecca M},
  title   = {{Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau}},
  journal = {Brain communications},
  year    = {2024},
  doi     = {10.1093/braincomms/fcae100},
  pmid    = {38585667},
  url     = {https://doi.org/10.1093/braincomms/fcae100}
}

@article{abdallah2024-38586442,
  author  = {Abdallah, A. E.},
  title   = {{Review on anti-alzheimer drug development: approaches, challenges and perspectives}},
  journal = {RSC advances},
  year    = {2024},
  doi     = {10.1039/d3ra08333k},
  pmid    = {38586442},
  url     = {https://doi.org/10.1039/d3ra08333k}
}

@article{ivanidze2026-42055956,
  author  = {Ivanidze, Jana and Gardella, Jae and Olson, Ahlanna and Sun, Shuo Mila and Thomas, Charlene and Wong, Oi Lee and Intorcia, Brielle and Moirano, Joseph and others},
  title   = {{PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy}},
  journal = {American Journal of Neuroradiology},
  year    = {2026},
  doi     = {10.3174/ajnr.a9387},
  pmid    = {42055956},
  url     = {https://doi.org/10.3174/ajnr.a9387}
}

@article{cummings2024-37955845,
  author  = {Cummings, J. and Osse, A. M. L. and Cammann, D. and Powell, J. and Chen, J.},
  title   = {{Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease}},
  journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
  year    = {2024},
  doi     = {10.1007/s40259-023-00633-2},
  pmid    = {37955845},
  url     = {https://doi.org/10.1007/s40259-023-00633-2}
}

@article{zhang2024-39174535,
  author  = {Zhang, J. and Zhang, Y. and Wang, J. and Xia, Y. and Chen, L.},
  title   = {{Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies}},
  journal = {Signal transduction and targeted therapy},
  year    = {2024},
  doi     = {10.1038/s41392-024-01911-3},
  pmid    = {39174535},
  url     = {https://doi.org/10.1038/s41392-024-01911-3}
}

@article{kim2025-39865265,
  author  = {Kim, B. H. and Kim, S. and Nam, Y. and Park, Y. H. and Shin, S. M. and Moon, M.},
  title   = {{Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives}},
  journal = {Translational neurodegeneration},
  year    = {2025},
  doi     = {10.1186/s40035-025-00465-w},
  pmid    = {39865265},
  url     = {https://doi.org/10.1186/s40035-025-00465-w}
}

@article{doran2024-38312931,
  author  = {Doran, S. J. and Sawyer, R. P.},
  title   = {{Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications}},
  journal = {Frontiers in neuroscience},
  year    = {2024},
  doi     = {10.3389/fnins.2024.1326784},
  pmid    = {38312931},
  url     = {https://doi.org/10.3389/fnins.2024.1326784}
}

@article{alkhalifa2025-41003140,
  author  = {Alkhalifa, A. E. and Al Mokhlf, A. and Ali, H. and Al-Ghraiybah, N. F. and Syropoulou, V.},
  title   = {{Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection}},
  journal = {Journal of personalized medicine},
  year    = {2025},
  doi     = {10.3390/jpm15090437},
  pmid    = {41003140},
  url     = {https://doi.org/10.3390/jpm15090437}
}

@article{jeong2024-39109501,
  author  = {Jeong, S. Y. and Suh, C. H. and Kim, S. J. and Lemere, C. A. and Lim, J. S. and Lee, J. H.},
  title   = {{Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring}},
  journal = {Korean journal of radiology},
  year    = {2024},
  doi     = {10.3348/kjr.2024.0105},
  pmid    = {39109501},
  url     = {https://doi.org/10.3348/kjr.2024.0105}
}

@article{vukmir2024-38939962,
  author  = {Vukmir, R. B.},
  title   = {{Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy}},
  journal = {Annals of clinical and translational neurology},
  year    = {2024},
  doi     = {10.1002/acn3.52042},
  pmid    = {38939962},
  url     = {https://doi.org/10.1002/acn3.52042}
}

@article{yang2025-40650049,
  author  = {Yang, H. M.},
  title   = {{Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies}},
  journal = {International journal of molecular sciences},
  year    = {2025},
  doi     = {10.3390/ijms26136271},
  pmid    = {40650049},
  url     = {https://doi.org/10.3390/ijms26136271}
}

@article{schreiber2025-41042497,
  author  = {Schreiber, C. P. and Kovacik, A. and Bishop, J. and Helman, J.},
  title   = {{Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers}},
  journal = {Drugs \& aging},
  year    = {2025},
  doi     = {10.1007/s40266-025-01253-x},
  pmid    = {41042497},
  url     = {https://doi.org/10.1007/s40266-025-01253-x}
}

@article{kurkinen2023-37831471,
  author  = {Kurkinen, Markku},
  title   = {{Donanemab: Not two without a third}},
  journal = {Advances in clinical and experimental medicine : official organ Wroclaw Medical University},
  year    = {2023},
  doi     = {10.17219/acem/172673},
  pmid    = {37831471},
  url     = {https://doi.org/10.17219/acem/172673}
}

@article{hardy2023-36797987,
  author  = {Hardy, John and Mummery, Catherine},
  title   = {{An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?}},
  journal = {Brain : a journal of neurology},
  year    = {2023},
  doi     = {10.1093/brain/awad049},
  pmid    = {36797987},
  url     = {https://doi.org/10.1093/brain/awad049}
}

@article{schnieder2026-42714614,
  author  = {Schnieder, Marlena},
  title   = {{[Antibody therapy in Alzheimer's disease]}},
  journal = {Zeitschrift fur Gerontologie und Geriatrie},
  year    = {2026},
  doi     = {10.1007/s00391-026-02640-8},
  pmid    = {42714614},
  url     = {https://doi.org/10.1007/s00391-026-02640-8}
}

@article{papaliagkas2025-41096797,
  author  = {Papaliagkas, Vasileios T.},
  title   = {{Anti-Amyloid Therapies for Alzheimer’s Disease: Progress, Pitfalls, and the Path Ahead}},
  journal = {International Journal of Molecular Sciences},
  year    = {2025},
  doi     = {10.3390/ijms26199529},
  pmid    = {41096797},
  url     = {https://doi.org/10.3390/ijms26199529}
}

@article{gordiichuk2025-12954b56,
  author  = {Gordiichuk, O. and Bulekhovets, M. and Bezhuk, S. and Omelianchyk, N. and Popshe, D.},
  title   = {{Monoclonal antibodies for treatment Alzheimer`s disease}},
  journal = {Reports of Vinnytsia National Medical University},
  year    = {2025},
  doi     = {10.31393/reports-vnmedical-2025-29(4)-29},
  url     = {https://doi.org/10.31393/reports-vnmedical-2025-29(4)-29}
}

@article{ricaurtefajardo2025-39805666,
  author  = {Ricaurte‐Fajardo, Andres and Ivanidze, Jana and Zhang, D. and Mahmud, Meem and Yasen, Weiye and Ravdin, Lisa and Pahlajani, Silky and de Leon, Mony and others},
  title   = {{Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?}},
  journal = {American Journal of Neuroradiology},
  year    = {2025},
  doi     = {10.3174/ajnr.a8654},
  pmid    = {39805666},
  url     = {https://doi.org/10.3174/ajnr.a8654}
}

@article{hoang2026-42125995,
  author  = {Hoang, M. T. and Kahn, J. G. and Saha, S. and Trépel, D.},
  title   = {{Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis}},
  journal = {Alzheimer's \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71308},
  pmid    = {42125995},
  url     = {https://doi.org/10.1002/alz.71308}
}

@article{ron2025-39094686,
  author  = {Ron, Handels and Herring William, L. and Sabine, Grimm and Anders, Sköldunger and Bengt, Winblad and Anders, Wimo and Linus, Jönsson},
  title   = {{New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases}},
  journal = {Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year    = {2025},
  doi     = {10.1016/j.jval.2024.07.009},
  pmid    = {39094686},
  url     = {https://doi.org/10.1016/j.jval.2024.07.009}
}

@article{cummings2023-37060386,
  author  = {Cummings, J.},
  title   = {{Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics}},
  journal = {Drugs},
  year    = {2023},
  doi     = {10.1007/s40265-023-01858-9},
  pmid    = {37060386},
  url     = {https://doi.org/10.1007/s40265-023-01858-9}
}

@article{tolar2021-34198582,
  author  = {Tolar, M. and Hey, J. and Power, A. and Abushakra, S.},
  title   = {{Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression}},
  journal = {International journal of molecular sciences},
  year    = {2021},
  doi     = {10.3390/ijms22126355},
  pmid    = {34198582},
  url     = {https://doi.org/10.3390/ijms22126355}
}

@article{peng2023-37600514,
  author  = {Peng, Y. and Jin, H. and Xue, Y. H. and Chen, Q. and Yao, S. Y. and Du, M. Q. and Liu, S.},
  title   = {{Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks}},
  journal = {Frontiers in aging neuroscience},
  year    = {2023},
  doi     = {10.3389/fnagi.2023.1206572},
  pmid    = {37600514},
  url     = {https://doi.org/10.3389/fnagi.2023.1206572}
}

@article{yadollahikhales2023-37490245,
  author  = {Yadollahikhales, G. and Rojas, J. C.},
  title   = {{Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2023},
  doi     = {10.1007/s13311-023-01405-0},
  pmid    = {37490245},
  url     = {https://doi.org/10.1007/s13311-023-01405-0}
}

@article{ramanan2023-37495380,
  author  = {Ramanan, V. K. and Armstrong, M. J. and Choudhury, P. and Coerver, K. A. and Hamilton, R. H. and Klein, B. C. and Wolk, D. A. and Wessels, SR. and others},
  title   = {{Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207757},
  pmid    = {37495380},
  url     = {https://doi.org/10.1212/wnl.0000000000207757}
}

@article{geerts2023-36632701,
  author  = {Geerts, H. and Walker, M. and Rose, R. and Bergeler, S. and van der Graaf, P. H. and Schuck, E. and Koyama, A. and Yasuda, S. and others},
  title   = {{A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease}},
  journal = {CPT: pharmacometrics \& systems pharmacology},
  year    = {2023},
  doi     = {10.1002/psp4.12912},
  pmid    = {36632701},
  url     = {https://doi.org/10.1002/psp4.12912}
}

@article{lu2023-37936917,
  author  = {Lu, O. and Kouser, T. and Skylar-Scott, I. A.},
  title   = {{Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies}},
  journal = {Frontiers in neurology},
  year    = {2023},
  doi     = {10.3389/fneur.2023.1241339},
  pmid    = {37936917},
  url     = {https://doi.org/10.3389/fneur.2023.1241339}
}

@article{hardy2025-40739944,
  author  = {Hardy, John},
  title   = {{Alzheimer's Disease: Treatment Challenges for the Future}},
  journal = {Journal of neurochemistry},
  year    = {2025},
  doi     = {10.1111/jnc.70176},
  pmid    = {40739944},
  url     = {https://doi.org/10.1111/jnc.70176}
}

@article{geldmacher2024-39620846,
  author  = {Geldmacher, David S},
  title   = {{Treatment of Alzheimer Disease}},
  journal = {Continuum (Minneapolis, Minn.)},
  year    = {2024},
  doi     = {10.1212/con.0000000000001503},
  pmid    = {39620846},
  url     = {https://doi.org/10.1212/con.0000000000001503}
}

@article{suzuki2024-38945936,
  author  = {Suzuki, Naoyuki and Hatta, Takuya and Ito, Mana and Kusakabe, Ken-Ichi},
  title   = {{Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives}},
  journal = {Chemical \& pharmaceutical bulletin},
  year    = {2024},
  doi     = {10.1248/cpb.c24-00069},
  pmid    = {38945936},
  url     = {https://doi.org/10.1248/cpb.c24-00069}
}

@article{cummings2025-40118715,
  author  = {Cummings, Jeffrey L},
  title   = {{Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2025},
  doi     = {10.1016/j.neurot.2025.e00570},
  pmid    = {40118715},
  url     = {https://doi.org/10.1016/j.neurot.2025.e00570}
}

@article{hoilundcarlsen2024-38830549,
  author  = {Høilund-Carlsen, Poul F and Alavi, Abass and Barrio, Jorge R and Castellani, Rudolph J and Costa, Tommaso and Herrup, Karl and Kepp, Kasper P and Neve, Rachael L and others},
  title   = {{Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit}},
  journal = {Ageing research reviews},
  year    = {2024},
  doi     = {10.1016/j.arr.2024.102348},
  pmid    = {38830549},
  url     = {https://doi.org/10.1016/j.arr.2024.102348}
}

@article{park2024-38932758,
  author  = {Park, Kyung Won},
  title   = {{Anti-amyloid Antibody Therapies for Alzheimer's Disease}},
  journal = {Nuclear medicine and molecular imaging},
  year    = {2024},
  doi     = {10.1007/s13139-024-00848-3},
  pmid    = {38932758},
  url     = {https://doi.org/10.1007/s13139-024-00848-3}
}

@article{ota2025-41047647,
  author  = {Ota, Miho and Arai, Tetsuaki},
  title   = {{[Pharmacological Interventions in Dementia]}},
  journal = {No shinkei geka. Neurological surgery},
  year    = {2025},
  doi     = {10.11477/mf.030126030530050943},
  pmid    = {41047647},
  url     = {https://doi.org/10.11477/mf.030126030530050943}
}

@article{hunter2024-39443750,
  author  = {Hunter, Philip},
  title   = {{The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy}},
  journal = {EMBO reports},
  year    = {2024},
  doi     = {10.1038/s44319-024-00294-4},
  pmid    = {39443750},
  url     = {https://doi.org/10.1038/s44319-024-00294-4}
}

@article{song2024-38758223,
  author  = {Song, Tanya and Wang, Yunfei and Silverglate, Bret David and Grossberg, George T},
  title   = {{Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's}},
  journal = {Expert opinion on drug metabolism \& toxicology},
  year    = {2024},
  doi     = {10.1080/17425255.2024.2357637},
  pmid    = {38758223},
  url     = {https://doi.org/10.1080/17425255.2024.2357637}
}

@article{saido2025-40899945,
  author  = {Saido, Takaomi C and Iwata, Nobuhisa},
  title   = {{The tale of donanemab: God is in the details}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2025},
  doi     = {10.1177/13872877251371240},
  pmid    = {40899945},
  url     = {https://doi.org/10.1177/13872877251371240}
}

@article{hoilundcarlsen2024-38612701,
  author  = {Høilund-Carlsen, Poul F and Alavi, Abass and Castellani, Rudolph J and Neve, Rachael L and Perry, George and Revheim, Mona-Elisabeth and Barrio, Jorge R},
  title   = {{Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?}},
  journal = {International journal of molecular sciences},
  year    = {2024},
  doi     = {10.3390/ijms25073892},
  pmid    = {38612701},
  url     = {https://doi.org/10.3390/ijms25073892}
}

@article{shinohara2024-39370836,
  author  = {Shinohara, Moeko and Ono, Kenjiro},
  title   = {{[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]}},
  journal = {Brain and nerve = Shinkei kenkyu no shinpo},
  year    = {2024},
  doi     = {10.11477/mf.1416202747},
  pmid    = {39370836},
  url     = {https://doi.org/10.11477/mf.1416202747}
}

@article{bhattacharya2025-39815655,
  author  = {Bhattacharya, Radha Shree and Singh, Raghuraj and Panghal, Archna and Thakur, Ashima and Singh, Lachhman and Verma, Rahul Kumar and Singh, Charan and Goyal, Manoj and others},
  title   = {{Multi-Targeting Phytochemicals for Alzheimer's Disease}},
  journal = {Phytotherapy research : PTR},
  year    = {2025},
  doi     = {10.1002/ptr.8435},
  pmid    = {39815655},
  url     = {https://doi.org/10.1002/ptr.8435}
}

@article{sharma2025-40993929,
  author  = {Sharma, Chanchal and Mazumder, Avijit},
  title   = {{From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease}},
  journal = {Central nervous system agents in medicinal chemistry},
  year    = {2025},
  doi     = {10.2174/0118715249388723250910140541},
  pmid    = {40993929},
  url     = {https://doi.org/10.2174/0118715249388723250910140541}
}

@article{besin2025-40951730,
  author  = {Besin, Valentinus and Humardani, Farizky Martriano and Yudiarto, Fenny Lanawati and Ong, Paulus Anam and Putra, Sulistyo Emantoko Dwi and Ningrum, Ratih Asmana},
  title   = {{Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele}},
  journal = {Chronic diseases and translational medicine},
  year    = {2025},
  doi     = {10.1002/cdt3.70006},
  pmid    = {40951730},
  url     = {https://doi.org/10.1002/cdt3.70006}
}

@article{vejandla2024-38313929,
  author  = {Vejandla, Bhuvanasai and Savani, Sarah and Appalaneni, Rohith and Veeravalli, Rithik S and Gude, Sai Sravya},
  title   = {{Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease}},
  journal = {Cureus},
  year    = {2024},
  doi     = {10.7759/cureus.51705},
  pmid    = {38313929},
  url     = {https://doi.org/10.7759/cureus.51705}
}

@article{godugu2025-41562774,
  author  = {Godugu, Deepika and Gattu, Kranthi and Suri, Parul and Daartey, Abel B and Jadhav, Krishna and Rojekar, Satish},
  title   = {{Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches}},
  journal = {Antibodies (Basel, Switzerland)},
  year    = {2025},
  doi     = {10.3390/antib15010001},
  pmid    = {41562774},
  url     = {https://doi.org/10.3390/antib15010001}
}

@article{kumar2024-38270120,
  author  = {Kumar, Ashish and Kim, Fred and Song, Dong-Keun and Choung, Jai Jun},
  title   = {{Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders}},
  journal = {Aging and disease},
  year    = {2024},
  doi     = {10.14336/ad.2023.1129},
  pmid    = {38270120},
  url     = {https://doi.org/10.14336/ad.2023.1129}
}

@article{brodtmann2023-36934371,
  author  = {Brodtmann, Amy G. and Darby, David and Oboudiyat, Carly and Mahoney, Colin and Le Heron, Campbell J. and Panegyres, Peter K. and Brew, Bruce J.},
  title   = {{Assessing preparedness for Alzheimer disease‐modifying therapies in Australasian health care systems}},
  journal = {The Medical Journal of Australia},
  year    = {2023},
  doi     = {10.5694/mja2.51880},
  pmid    = {36934371},
  url     = {https://doi.org/10.5694/mja2.51880}
}

@article{wang2023-37639461,
  author  = {Wang, Y. T. and Rosa-Neto, P. and Gauthier, S.},
  title   = {{Advanced brain imaging for the diagnosis of Alzheimer disease}},
  journal = {Current opinion in neurology},
  year    = {2023},
  doi     = {10.1097/wco.0000000000001198},
  pmid    = {37639461},
  url     = {https://doi.org/10.1097/wco.0000000000001198}
}

@article{hoilundcarlsen2023-37314733,
  author  = {Høilund-Carlsen, P. F. and Revheim, M. E. and Alavi, A. and Barrio, JR.},
  title   = {{FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease}},
  journal = {Clinical nuclear medicine},
  year    = {2023},
  doi     = {10.1097/rlu.0000000000004710},
  pmid    = {37314733},
  url     = {https://doi.org/10.1097/rlu.0000000000004710}
}

@article{waite2024-38962384,
  author  = {Waite, L. M.},
  title   = {{New and emerging drug therapies for Alzheimer disease}},
  journal = {Australian prescriber},
  year    = {2024},
  doi     = {10.18773/austprescr.2024.021},
  pmid    = {38962384},
  url     = {https://doi.org/10.18773/austprescr.2024.021}
}

@article{vejdanijahromi2026-41781178,
  author  = {Vejdani-Jahromi, Maryam and Calle, Esteban and Ganem, Odette and Rohatgi, Saurabh and Farzaneh, Hana and Griffin, Harry and Zhu, Shenghua and Seah, Jarrel C. Y. and others},
  title   = {{Relationship between APOE Genotype Status and Imaging Features in Patients with Alzheimer Disease Being Considered for Antiamyloid β Therapy}},
  journal = {American Journal of Neuroradiology},
  year    = {2026},
  doi     = {10.3174/ajnr.a9056},
  pmid    = {41781178},
  url     = {https://doi.org/10.3174/ajnr.a9056}
}

@article{rubin2025-40844810,
  author  = {Rubin, Rita},
  title   = {{Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows}},
  journal = {JAMA},
  year    = {2025},
  doi     = {10.1001/jama.2025.14180},
  pmid    = {40844810},
  url     = {https://doi.org/10.1001/jama.2025.14180}
}

@article{price2025-40435868,
  author  = {Price, Price Udo and Heggie, Robert and Moriguti, Júlio César and Pereira, Leonardo Régis Leira},
  title   = {{Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil}},
  journal = {Value in Health Regional Issues},
  year    = {2025},
  doi     = {10.1016/j.vhri.2025.101130},
  pmid    = {40435868},
  url     = {https://doi.org/10.1016/j.vhri.2025.101130}
}

@article{cogswell2025-39179297,
  author  = {Cogswell, P. M. and Andrews, T. J. and Barakos, J. A. and Barkhof, F. and Bash, S. and Benayoun, M. D. and Chiang, G. C. and Franceschi, A. M. and others},
  title   = {{Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities}},
  journal = {AJNR. American journal of neuroradiology},
  year    = {2025},
  doi     = {10.3174/ajnr.a8469},
  pmid    = {39179297},
  url     = {https://doi.org/10.3174/ajnr.a8469}
}

@article{doggrell2024-38414336,
  author  = {Doggrell, S. A.},
  title   = {{More failure with solanezumab - this time in preclinical Alzheimer's disease}},
  journal = {Expert opinion on biological therapy},
  year    = {2024},
  doi     = {10.1080/14712598.2024.2325551},
  pmid    = {38414336},
  url     = {https://doi.org/10.1080/14712598.2024.2325551}
}

@article{francis2025-40940304,
  author  = {Francis, E. and Paylor, S. and Van, C. and Mathews, B. and Sobhanian, M. J. and Mansour, D. Z. and Hennawi, G. and Brandt, N. J.},
  title   = {{Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer's disease}},
  journal = {Expert review of clinical pharmacology},
  year    = {2025},
  doi     = {10.1080/17512433.2025.2556122},
  pmid    = {40940304},
  url     = {https://doi.org/10.1080/17512433.2025.2556122}
}

@article{guo2025-41107537,
  author  = {Guo, X. and Yue, R. and Cui, Z. and Wang, S. and Jia, T. and Li, W. and Zhang, W. and Shan, L. and others},
  title   = {{Advances of therapeutic strategies for Alzheimer's disease}},
  journal = {Journal of neurology},
  year    = {2025},
  doi     = {10.1007/s00415-025-13456-8},
  pmid    = {41107537},
  url     = {https://doi.org/10.1007/s00415-025-13456-8}
}

@article{elamin2025-41077117,
  author  = {Elamin, S. A. and Al Shibli, A. N. and Shaito, A. and Al-Maadhadi, M. J. M. B. and Zolezzi, M. and Pedersen, S.},
  title   = {{Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review}},
  journal = {Neuroscience},
  year    = {2025},
  doi     = {10.1016/j.neuroscience.2025.10.011},
  pmid    = {41077117},
  url     = {https://doi.org/10.1016/j.neuroscience.2025.10.011}
}

@article{fedele2023-37833948,
  author  = {Fedele, Ernesto},
  title   = {{Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis}},
  journal = {International journal of molecular sciences},
  year    = {2023},
  doi     = {10.3390/ijms241914499},
  pmid    = {37833948},
  url     = {https://doi.org/10.3390/ijms241914499}
}

@article{villain2022-35489824,
  author  = {Villain, N},
  title   = {{Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?}},
  journal = {Revue neurologique},
  year    = {2022},
  doi     = {10.1016/j.neurol.2022.02.456},
  pmid    = {35489824},
  url     = {https://doi.org/10.1016/j.neurol.2022.02.456}
}

@article{varadharajan2023-38059250,
  author  = {Varadharajan, Ashvin and Davis, Aarjith Damian and Ghosh, Aishwarya and Jagtap, Tejaswini and Xavier, Anjo and Menon, Anjana Jayakumar and Roy, Dwaiti and Gandhi, Sandhya and others},
  title   = {{Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs}},
  journal = {Journal of neurosciences in rural practice},
  year    = {2023},
  doi     = {10.25259/jnrp_356_2023},
  pmid    = {38059250},
  url     = {https://doi.org/10.25259/jnrp_356_2023}
}

@article{johannesson2021-34091073,
  author  = {Johannesson, Malin and Sahlin, Charlotte and Söderberg, Linda and Basun, Hans and Fälting, Johanna and Möller, Christer and Zachrisson, Olof and Sunnemark, Dan and others},
  title   = {{Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease}},
  journal = {Molecular and cellular neurosciences},
  year    = {2021},
  doi     = {10.1016/j.mcn.2021.103641},
  pmid    = {34091073},
  url     = {https://doi.org/10.1016/j.mcn.2021.103641}
}

@article{kim2024-39496112,
  author  = {Kim, H. Y. and Kim, Y.},
  title   = {{Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease}},
  journal = {Accounts of chemical research},
  year    = {2024},
  doi     = {10.1021/acs.accounts.4c00458},
  pmid    = {39496112},
  url     = {https://doi.org/10.1021/acs.accounts.4c00458}
}

@article{boxer2023-37848035,
  author  = {Boxer, A. L. and Sperling, R.},
  title   = {{Accelerating Alzheimer's therapeutic development: The past and future of clinical trials}},
  journal = {Cell},
  year    = {2023},
  doi     = {10.1016/j.cell.2023.09.023},
  pmid    = {37848035},
  url     = {https://doi.org/10.1016/j.cell.2023.09.023}
}

@article{barakos2022-35542992,
  author  = {Barakos, J. and Purcell, D. and Suhy, J. and Chalkias, S. and Burkett, P. and Marsica Grassi, C. and Castrillo-Viguera, C. and Rubino, I. and others},
  title   = {{Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2022},
  doi     = {10.14283/jpad.2022.21},
  pmid    = {35542992},
  url     = {https://doi.org/10.14283/jpad.2022.21}
}

@article{dangpiaei2026-41885326,
  author  = {Dangpiaei, S. and Kamal, K. M. and Shoair, O. A. and Al-Mamun, M. A.},
  title   = {{Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study}},
  journal = {Journal of managed care \& specialty pharmacy},
  year    = {2026},
  doi     = {10.18553/jmcp.2026.32.4.470},
  pmid    = {41885326},
  url     = {https://doi.org/10.18553/jmcp.2026.32.4.470}
}

@article{schindler2025-41442134,
  author  = {Schindler, Suzanne Elizabeth and Hofmann, Anna and Paczynski, Madeline and Posey, Zachary J and Aldinger, Melissa and Benzinger, Tammie L.S. and Morris, John C. and Snider, Barbara Joy},
  title   = {{Determining eligibility for anti‐amyloid treatments using blood biomarkers}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_097511},
  pmid    = {41442134},
  url     = {https://doi.org/10.1002/alz70856_097511}
}

@article{hafez2026-42084750,
  author  = {Hafez, Mohamed Mahmoud and Abbas, Haidy A. and Shoman, Nabil A. and Soubh, Ayman A. and Aly, Omnia and Sallam, Mohamed F. and Seliem, Mahmoud A. and Malaak, Fady A.},
  title   = {{A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease}},
  journal = {Journal of Neurology},
  year    = {2026},
  doi     = {10.1007/s00415-026-13829-7},
  pmid    = {42084750},
  url     = {https://doi.org/10.1007/s00415-026-13829-7}
}

@article{araujo2025-92b69fc6,
  author  = {ARAÚJO, Rodolfo Lima and BARROS, Gabrielly Martins da Silva and LEMOS, Mariana Pereira Duarte and MACHADO, Mario Neto Vieira},
  title   = {{ALZHEIMER E A EVOLUÇÃO DO TRATAMENTO NA ÚLTIMA DÉCADA: UMA REVISÃO DE LITERATURA}},
  journal = {JNT - Facit Business and Technology Journal},
  year    = {2025},
  doi     = {10.5281/zenodo.17193517},
  url     = {https://doi.org/10.5281/zenodo.17193517}
}

@article{finn2025-41260674,
  author  = {Finn, Quentin and Pascual, Belén and Schulz, Paul E. and Masdeu, Joseph C.},
  title   = {{β-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease}},
  journal = {American Journal of Neuroradiology},
  year    = {2025},
  doi     = {10.3174/ajnr.a9111},
  pmid    = {41260674},
  url     = {https://doi.org/10.3174/ajnr.a9111}
}

@article{grobner2026-42143322,
  author  = {Gröbner, Lea S. and Pietrzik, Claus U.},
  title   = {{Transport pathways across the blood-brain barrier for waste clearance and drug delivery}},
  journal = {Fluids and Barriers of the CNS},
  year    = {2026},
  doi     = {10.1186/s12987-026-00812-7},
  pmid    = {42143322},
  url     = {https://doi.org/10.1186/s12987-026-00812-7}
}

@article{hsu2025-40887393,
  author  = {Hsu, Jung‐Lung and Park, Kee Hyung and Panegyres, Peter K. and Huang, Yao Hsien and Eom, Young In and Prusty, Vinay and Tan, Lolita Stephanie and Shea, Yat Fung},
  title   = {{Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100362},
  pmid    = {40887393},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100362}
}

@article{maurizio2026-42306480,
  author  = {Maurizio, Giorelli and Di, Fazio Pasquale and Tiziana, Dimatteo},
  title   = {{Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis}},
  journal = {JAR life},
  year    = {2026},
  doi     = {10.1016/j.jarlif.2026.100076},
  pmid    = {42306480},
  url     = {https://doi.org/10.1016/j.jarlif.2026.100076}
}

@article{tayeb2023-37045461,
  author  = {Tayeb, H. O. and Khallaf, R. A. and Muayqil, T. A. and Alkeridy, W. A. and Alibrahim, F. S. and Alfaify, O. A. and Qadi, N. and Tarazi, F. I.},
  title   = {{The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology}},
  journal = {Neurosciences (Riyadh, Saudi Arabia)},
  year    = {2023},
  doi     = {10.17712/nsj.2023.2.20220133},
  pmid    = {37045461},
  url     = {https://doi.org/10.17712/nsj.2023.2.20220133}
}

@article{bhagunde2026-41543367,
  author  = {Bhagunde, Pratik R. and Penner, Natasha and Willis, Brian A. and Bell, Robert and Charil, Arnaud and Irizarry, Michael C. and Hersch, Steven J. and Reyderman, Larisa},
  title   = {{Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model}},
  journal = {CPT Pharmacometrics \& Systems Pharmacology},
  year    = {2026},
  doi     = {10.1002/psp4.70173},
  pmid    = {41543367},
  url     = {https://doi.org/10.1002/psp4.70173}
}

@article{hendriks2026-4ee39e2d,
  author  = {Hendriks, J. and Antoniou, M. and Babic, I.},
  title   = {{Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease}},
  journal = {Zenodo (CERN European Organization for Nuclear Research)},
  year    = {2026},
  doi     = {10.5281/zenodo.22310606},
  url     = {https://doi.org/10.5281/zenodo.22310606}
}

@article{wang2025-40911712,
  author  = {Wang, Guoqiao and Li, Yan and McDade, Eric and Xiong, Chengjie and Hartz, Sarah M. and Bateman, Randall John and Morris, John C. and Schneider, Lon S. S. and others},
  title   = {{Clinical progression on CDR‐SB©: Progression‐free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70643},
  pmid    = {40911712},
  url     = {https://doi.org/10.1002/alz.70643}
}

@article{elghanam2024-38669547,
  author  = {Elghanam, Y. and Purja, S. and Kim, E. Y.},
  title   = {{Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240008},
  pmid    = {38669547},
  url     = {https://doi.org/10.3233/jad-240008}
}

@article{flicker2025-40511512,
  author  = {Flicker, L.},
  title   = {{Antiamyloid treatment for dementia: concerns outweigh hopes}},
  journal = {Current opinion in psychiatry},
  year    = {2025},
  doi     = {10.1097/yco.0000000000001021},
  pmid    = {40511512},
  url     = {https://doi.org/10.1097/yco.0000000000001021}
}

@article{benzinger2025-41447186,
  author  = {Benzinger, Tammie L.S. and Charil, Arnaud and Gordon, Brian Andrew and Flores, Shaney E. and Hornbeck, Russ C. and Wildsmith, Kristin R. and Banerjee, Sibabrata and Wang, Guoqiao and others},
  title   = {{Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_105301},
  pmid    = {41447186},
  url     = {https://doi.org/10.1002/alz70859_105301}
}

@article{kyohei2026-42019137,
  author  = {Kyohei, Otani and Hiroyuki, Ishihara and Tetsu, Nakamura and Kana, Kawabe},
  title   = {{Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center}},
  journal = {General hospital psychiatry},
  year    = {2026},
  doi     = {10.1016/j.genhosppsych.2026.04.006},
  pmid    = {42019137},
  url     = {https://doi.org/10.1016/j.genhosppsych.2026.04.006}
}

@article{beveridge2024-38193477,
  author  = {Beveridge, J. and Kaniecki, E. and Naidu, A. and Silverglate, B. D. and Grossberg, G.},
  title   = {{How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?}},
  journal = {Expert opinion on emerging drugs},
  year    = {2024},
  doi     = {10.1080/14728214.2024.2304059},
  pmid    = {38193477},
  url     = {https://doi.org/10.1080/14728214.2024.2304059}
}

@article{das2025-40639927,
  author  = {Das, S.K.},
  title   = {{Alzheimer’s disease basics: we all should know}},
  journal = {Neurological Research},
  year    = {2025},
  doi     = {10.1080/01616412.2025.2529560},
  pmid    = {40639927},
  url     = {https://doi.org/10.1080/01616412.2025.2529560}
}

@article{zupan2026-42688139,
  author  = {Zupan, Matija and Prelog, Polona Rus and Kramberger, Milica Gregorič and Frol, Senta},
  title   = {{Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions}},
  journal = {Frontiers in Neurology},
  year    = {2026},
  doi     = {10.3389/fneur.2026.1889769},
  pmid    = {42688139},
  url     = {https://doi.org/10.3389/fneur.2026.1889769}
}

@article{nahal2026-41810890,
  author  = {Nahal, Danica Juričić and Mas, Petar and Cegec, Ivana and Bego, Margareta and Domjanović, Iva Klarica},
  title   = {{Anti‐amyloid antibodies in Europe: Where are we now?}},
  journal = {British Journal of Clinical Pharmacology},
  year    = {2026},
  doi     = {10.1002/bcp.70526},
  pmid    = {41810890},
  url     = {https://doi.org/10.1002/bcp.70526}
}

@article{ishibashi2025-40108731,
  author  = {Ishibashi, Kenji and Kurihara, Masanori and Ihara, Ryoko},
  title   = {{Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases}},
  journal = {Clinical Nuclear Medicine},
  year    = {2025},
  doi     = {10.1097/rlu.0000000000005842},
  pmid    = {40108731},
  url     = {https://doi.org/10.1097/rlu.0000000000005842}
}

@article{singh2025-1ee39399,
  author  = {Singh, Asem Surindro and Naqvi, Afsar Raza and Chanu, Machathoibi Takhellambam},
  title   = {{Neuroinflammation and progress in clinical trials for the treatment of Alzheimer’s disease and related dementias: An update}},
  journal = {Innovative Medicines \& Omics},
  year    = {2025},
  doi     = {10.36922/imo025050007},
  url     = {https://doi.org/10.36922/imo025050007}
}

@article{bhati2026-0a449f11,
  author  = {Bhati, Sampat Singh and Tanwar, Sampat Singh},
  title   = {{Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions}},
  journal = {Discover Neuroscience},
  year    = {2026},
  doi     = {10.1186/s13064-026-00295-0},
  url     = {https://doi.org/10.1186/s13064-026-00295-0}
}

@article{knupflemacher2025-3c483de3,
  author  = {Knupflemacher, Daniel Sánchez and García, Xavier Antonio Sánchez and Salgado, Celina Nicole Angulo and Loyola, Paula Robert and Arce, Joel Santiago and Bautista, Ángel Gabriel Pérez},
  title   = {{Terapias emergentes para la enfermedad de Alzheimer: revisión sistemática de anticuerpos anti-amiloide y mecanismos alternativos}},
  journal = {Revista Científica de Salud y Desarrollo Humano},
  year    = {2025},
  doi     = {10.61368/r.s.d.h.v6i2.661},
  url     = {https://doi.org/10.61368/r.s.d.h.v6i2.661}
}

@article{dinnerstein2026-42318437,
  author  = {Dinnerstein, Eric},
  title   = {{“Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection}},
  journal = {Alzheimer s \& Dementia Diagnosis Assessment \& Disease Monitoring},
  year    = {2026},
  doi     = {10.1002/dad2.70373},
  pmid    = {42318437},
  url     = {https://doi.org/10.1002/dad2.70373}
}

@article{gonzalezrodriguez2026-42435702,
  author  = {González-Rodríguez, Víctor Manuel and Martín-López, Esther},
  title   = {{En respuesta a «Avances y controversias de los tratamientos de la enfermedad de Alzheimer»}},
  journal = {Atención Primaria},
  year    = {2026},
  doi     = {10.1016/j.aprim.2026.103570},
  pmid    = {42435702},
  url     = {https://doi.org/10.1016/j.aprim.2026.103570}
}

@article{martinez2026-d85edb6b,
  author  = {Martínez, David A. Pérez},
  title   = {{Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: ¿estamos preparados?}},
  journal = {Kranion},
  year    = {2026},
  doi     = {10.24875/kranion.m26000124},
  url     = {https://doi.org/10.24875/kranion.m26000124}
}

@article{study2025-41130241,
  title   = {{Neue Alzheimer-Therapien: Vortrag zu ARIA für eine sichere MRT-Diagnostik}},
  journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
  year    = {2025},
  doi     = {10.1055/a-2690-5210},
  pmid    = {41130241},
  url     = {https://doi.org/10.1055/a-2690-5210}
}

@article{study2025-41130242,
  title   = {{Interview – Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen müssen}},
  journal = {RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren},
  year    = {2025},
  doi     = {10.1055/a-2690-4869},
  pmid    = {41130242},
  url     = {https://doi.org/10.1055/a-2690-4869}
}

@article{rajagopalan2025-5adb338a,
  author  = {Rajagopalan, Ramanathan and Hariharan, Sujatha and Akshaya, N.R. and Senthamarai, R.},
  title   = {{A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer}},
  journal = {Global Journal of Medical Pharmaceutical and Biomedical Update},
  year    = {2025},
  doi     = {10.25259/gjmpbu_38_2024},
  url     = {https://doi.org/10.25259/gjmpbu_38_2024}
}

@article{gauri2026-f13bd11e,
  author  = {Gauri and Goyal, Anju and Singh, Jitender and Sudan, Puneet and Sharma, Sachin Kumar},
  title   = {{NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER}},
  journal = {Genetics and Molecular Research},
  year    = {2026},
  doi     = {10.4238/0fganh12},
  url     = {https://doi.org/10.4238/0fganh12}
}

@article{schwarz2025-69d2f1b5,
  author  = {Schwarz, EP},
  title   = {{Nieuwe geneesmiddelen bij Alzheimer - Update}},
  journal = {Geneesmiddelenbulletin},
  year    = {2025},
  doi     = {10.35351/gebu.nl.2025.11.30},
  url     = {https://doi.org/10.35351/gebu.nl.2025.11.30}
}

@article{fonseca2025-b2f98913,
  author  = {Fonseca, Bruno Souza and Cordeiro, Matheus Henrique de Lima and Abreu, Pedro Henrique and Takahashi, Yuji},
  title   = {{Anticorpos anti-amiloide no tratamento da Doença de Alzheimer: uma revisão narrativa}},
  journal = {Revista Sociedade Científica},
  year    = {2025},
  doi     = {10.61411/rsc202593118},
  url     = {https://doi.org/10.61411/rsc202593118}
}

@article{araujo2025-2e796461,
  author  = {ARAÚJO, Rodolfo Lima and BARROS, Gabrielly Martins da Silva and LEMOS, Mariana Pereira Duarte and MACHADO, Mario Neto Vieira},
  title   = {{ALZHEIMER E A EVOLUÇÃO DO TRATAMENTO NA ÚLTIMA DÉCADA: UMA REVISÃO DE LITERATURA}},
  journal = {JNT - Facit Business and Technology Journal},
  year    = {2025},
  doi     = {10.5281/zenodo.17193516},
  url     = {https://doi.org/10.5281/zenodo.17193516}
}

@article{lateef2025-92541794,
  author  = {Lateef, Uswa and Junaid, Aroob and Saeed, Khansa and Khalil, Habiba and Tasaddiq, Musfira and Malik, Dr. Maria},
  title   = {{REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS}},
  journal = {Journal of medical \& health sciences review.},
  year    = {2025},
  doi     = {10.65035/w1y9ey43},
  url     = {https://doi.org/10.65035/w1y9ey43}
}

@article{michalak2025-aa1cc3c7,
  author  = {Michalak, Mateusz and Kucharczyk, Piotr and Parzęcka, Karolina and Symulewicz, Michał and Domaradzki, Olaf and Zań, Weronika and Kusy, Bartłomiej and Stolińska, Marta and others},
  title   = {{Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature review}},
  journal = {Journal of Education Health and Sport},
  year    = {2025},
  doi     = {10.12775/jehs.2025.80.49304},
  url     = {https://doi.org/10.12775/jehs.2025.80.49304}
}

@article{bombonalban2026-7db0e4e9,
  author  = {Bombón-Albán, Paulina Elizabeth},
  title   = {{Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular}},
  journal = {Acta neurológica colombiana},
  year    = {2026},
  doi     = {10.22379/anc.2188},
  url     = {https://doi.org/10.22379/anc.2188}
}

@article{nogueira2025-3d634112,
  author  = {Nogueira, Guilherme Nobre and Filho, Jarbas de Sá Roriz and Gonçalves, Rafaela Fernandes and Ribeiro, Maroan Soraia Santos Navas and Isolan, Gustavo Rassier},
  title   = {{Avanços na doença de Alzheimer: diagnóstico precoce, biomarcadores e perspectivas futuras}},
  journal = {BioSCIENCE},
  year    = {2025},
  doi     = {10.55684/2025.83.s1.e00009},
  url     = {https://doi.org/10.55684/2025.83.s1.e00009}
}

@article{leonjustel2025-520c3a35,
  author  = {León‐Justel, Antonio and Sánchez-Fernández, Félix and Viñuela-Fernández, Félix and Ortega-Ortega, Fernando F. and Olivas-Martínez, Israel and López-Domínguez, Jose M. and Menéndez-Valladares, Paloma and Pérez-Noguera, Rafael},
  title   = {{Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantación en un hospital de tercer nivel}},
  journal = {Kranion},
  year    = {2025},
  doi     = {10.24875/kranion.m25000107},
  url     = {https://doi.org/10.24875/kranion.m25000107}
}

@article{gonzalez2025-f695fc6b,
  author  = {González, Yanliel Feliciano and González, Nanelli Feliciano},
  title   = {{Model of the Impact of Pharmacological and Non-pharmacological Treatment of Alzheimer’s Disease}},
  journal = {[in]genio revista de investigación y labor creativa},
  year    = {2025},
  doi     = {10.54114/ingeniosv12i1.10262},
  url     = {https://doi.org/10.54114/ingeniosv12i1.10262}
}

@article{eric2026-42594414,
  author  = {Eric, Dinnerstein},
  title   = {{The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2026},
  doi     = {10.1016/j.tjpad.2026.100653},
  pmid    = {42594414},
  url     = {https://doi.org/10.1016/j.tjpad.2026.100653}
}

@article{study2025-0b1099e7,
  title   = {{Netzwerkmetaanalyse zu neuen Therapieoptionen bei Alzheimer Demenz}},
  journal = {Fortschritte der Neurologie · Psychiatrie},
  year    = {2025},
  doi     = {10.1055/a-2523-9611},
  url     = {https://doi.org/10.1055/a-2523-9611}
}

@article{butler2025-35ab99e8,
  author  = {Butler, P. M. and Francis, A. and Meunier, A. L. and Anderson, A. K. and Hennessey, E. L. and Miller, M. B. and Lemere, C. A. and Selkoe, D. J. and others},
  title   = {{Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain}},
  journal = {bioRxiv},
  year    = {2025},
  doi     = {10.1101/2025.05.20.654902},
  url     = {https://doi.org/10.1101/2025.05.20.654902}
}

@article{ferrari2024-a3b419d0,
  author  = {Ferrari, IV.},
  title   = {{Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein}},
  journal = {Preprints.org},
  year    = {2024},
  doi     = {10.20944/preprints202402.0232.v1},
  url     = {https://doi.org/10.20944/preprints202402.0232.v1}
}

@article{nakai2026-ba303595,
  author  = {Nakai, T. and Koseki, T. and Watanabe, H. and Yamada, S.},
  title   = {{Drug-Drug Interaction Signals Between Anti-Amyloid-β Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.08.26362402},
  url     = {https://doi.org/10.64898/2026.09.08.26362402}
}

@article{hey2026-a02492d7,
  author  = {Hey, J. A. and Geerts, H. and Schaefer, J. F. and Short, S. M. and Graaf, P. and Abushakra, S. and Power, A. and Tolar, M. and others},
  title   = {{Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment}},
  journal = {Research Square},
  year    = {2026},
  doi     = {10.21203/rs.3.rs-10570608/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-10570608/v1}
}

@article{venturaantunes2026-4f28fca6,
  author  = {Ventura-Antunes, L. and Janve, V. A. and Womble, N. and Weasler, C. J. and Hai, S. A. and Brula, H. and Mobley, B. C. and Hohman, T. J. and others},
  title   = {{Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.10.19.759840},
  url     = {https://doi.org/10.64898/2026.10.19.759840}
}

@article{lajoie2026-fc03ab7d,
  author  = {La Joie, R. and Lin, M. and Wang, Y. and Soleimani-Meigooni, D. N. and Ellingson, T. and Nguyen, H. and Blazhenets, G. and Fonseca, C. S. and others},
  title   = {{When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy}},
  journal = {medRxiv},
  year    = {2026},
  doi     = {10.64898/2026.10.03.26364642},
  url     = {https://doi.org/10.64898/2026.10.03.26364642}
}

@article{algamal2026-005bc584,
  author  = {Algamal, M. and Yokomizo, S. and Ndambakuwa, W. and Abdallah, S. and Sanchez-Mico, M. V. and Gillani, R. and da Silva, P. and Rajput, A. and others},
  title   = {{Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-Aβ immunotherapy}},
  journal = {bioRxiv},
  year    = {2026},
  doi     = {10.64898/2026.09.07.749938},
  url     = {https://doi.org/10.64898/2026.09.07.749938}
}

@article{sen2026-e890aa4f,
  author  = {Sen, S. E.},
  title   = {{A Transferable Health Economic Evaluation Framework for Alzheimer’s Disease-Modifying Therapies}},
  journal = {Research Square},
  year    = {2026},
  doi     = {10.21203/rs.3.rs-9602832/v1},
  url     = {https://doi.org/10.21203/rs.3.rs-9602832/v1}
}

@article{study2024-6280b4fa,
  title   = {{Leqembi Recommended for Treatment of Early Alzheimer's Disease (CHMP re-examination, reversing July 2024 refusal)}},
  journal = {European Medicines Agency},
  year    = {2024}
}

@article{study2023-826d45e8,
  title   = {{FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval}},
  journal = {U.S. Food and Drug Administration},
  year    = {2023}
}

@article{study2024-49a9a379,
  title   = {{Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)}},
  journal = {Biogen Inc. press release},
  year    = {2024}
}

@article{study2022-ff44148a,
  title   = {{National Coverage Determination: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (NCD 200.3)}},
  journal = {Centers for Medicare \& Medicaid Services},
  year    = {2022}
}